



P.B.5818 – Patentlaan 2
2280 HV Rijswijk (ZH)
+31 70 340 2040
TX 31651 epo nl
FAX +31 70 340 3016

Europäisches
Patentamt

Zweigstelle
in Den Haag
Recherchen-
abteilung

European
Patent Office

Branch at
The Hague
Search
division

Office européen
des brevets

Département à
La Haye
Division de la
recherche

Bizley, Richard Edward
Hepworth, Lawrence, Bryer & Bizley
Merlin House
Falconry Court
Baker's Lane
Epping
Essex CM16 5DQ
GRANDE BRETAGNE

RECEIVED

23 JAN 2003

HLB3 RECORDS

PROVINCIAL MUS

Datum/Date

23.01.03

Zeichen/Ref./Réf.

APEP98846

Anmeldung Nr./Application No./Demande n°./Patent Nr./Patent No./Brevet n°.

96943512.2-2401-US9618807

Anmelder/Applicant/Demandeur/Patentinhaber/Proprietor/Titulaire

Athena Neurosciences, Inc.

COMMUNICATION

The European Patent Office herewith transmits as an enclosure the European search report for the above-mentioned European patent application.

If applicable, copies of the documents cited in the European search report are attached.

Additional set(s) of copies of the documents cited in the European search report is (are) enclosed as well.



REFUND OF THE SEARCH FEE

If applicable under Article 10 Rules relating to fees, a separate communication from the Receiving Section on the refund of the search fee will be sent later.



DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	<p>WO 95 19790 A (BENDIG MARY M ; SALDANHA JOSE (GB); JONES TARRAN S (GB); LEGER OLIV) 27 July 1995 (1995-07-27)</p> <p>* abstract *</p> <p>* page 1, line 8 - page 2, line 38 *</p> <p>* page 3, line 23 - page 5, line 3 *</p> <p>* page 11, line 30 - page 13, line 27 *</p> <p>* page 15, line 25 - page 18, line 3 *</p> <p>* page 24, line 10 - page 25, line 15 *</p> <p>* page 45, line 1-14 *</p> <p>* claims 1-16,27-29 *</p> <p>---</p>	1-10	A61K39/395
Y	<p>CYBULSKY M I ET AL: "Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis." SCIENCE. UNITED STATES 15 FEB 1991, vol. 251, no. 4995, 15 February 1991 (1991-02-15), pages 788-791, XP001097594</p> <p>ISSN: 0036-8075</p> <p>* abstract *</p> <p>---</p>	1-10	
Y	<p>TSUKAMOTO K ET AL: "Administration of monoclonal antibodies against vascular cell adhesion molecule-1/very late antigen-4 abrogates predisposing autoimmune diabetes in NOD mice." CELLULAR IMMUNOLOGY. UNITED STATES 15 OCT 1995, vol. 165, no. 2, 15 October 1995 (1995-10-15), pages 193-201, XP001097592</p> <p>ISSN: 0008-8749</p> <p>* abstract *</p> <p>---</p> <p>---</p>	1-10	C07K A61K
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
1	Place of search MUNICH	Date of completion of the search 13 January 2003	Examiner Montrone, M
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			



DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Y	PODOLSKY D K ET AL: "Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody." THE JOURNAL OF CLINICAL INVESTIGATION. UNITED STATES JUL 1993, vol. 92, no. 1, July 1993 (1993-07), pages 372-380, XP000749547 ISSN: 0021-9738 * abstract * ---	1-10	
Y	CHISHOLM P L ET AL: "Monoclonal antibodies to the integrin alpha-4 subunit inhibit the murine contact hypersensitivity response." EUROPEAN JOURNAL OF IMMUNOLOGY. GERMANY MAR 1993, vol. 23, no. 3, March 1993 (1993-03), pages 682-688, XP009003764 ISSN: 0014-2980 * abstract * ---	1-10	
Y	PAUL L C ET AL: "Monoclonal antibodies against LFA-1 and VLA-4 inhibit graft vasculitis in rat cardiac allografts." TRANSPLANTATION PROCEEDINGS. UNITED STATES FEB 1993, vol. 25, no. 1 Pt 1, February 1993 (1993-02), pages 813-814, XP009003749 ISSN: 0041-1345 * abstract * ---	1-10 -/-	
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
1	Place of search MUNICH	Date of completion of the search 13 January 2003	Examiner Montrone, M
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			



DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)																								
Y	WEG V B ET AL: "A monoclonal antibody recognizing very late activation antigen-4 inhibits eosinophil accumulation in vivo." THE JOURNAL OF EXPERIMENTAL MEDICINE. UNITED STATES 1 FEB 1993, vol. 177, no. 2, 1 February 1993 (1993-02-01), pages 561-566, XP009003765 ISSN: 0022-1007 * abstract * ---	1-10																									
Y	PRETOLANI M ET AL: "Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea pig airways." THE JOURNAL OF EXPERIMENTAL MEDICINE. UNITED STATES 1 SEP 1994, vol. 180, no. 3, 1 September 1994 (1994-09-01), pages 795-805, XP009003766 ISSN: 0022-1007 * abstract * ---	1-10																									
Y	SASSEVILLE V G ET AL: "Monocyte adhesion to endothelium in simian immunodeficiency virus-induced AIDS encephalitis is mediated by vascular cell adhesion molecule-1/alpha 4 beta 1 integrin interactions." AMERICAN JOURNAL OF PATHOLOGY. UNITED STATES JAN 1994, vol. 144, no. 1, January 1994 (1994-01), pages 27-40, XP009003767 ISSN: 0002-9440 * abstract * ---	1-10																									
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)																								
1	The supplementary search report has been based on the last set of claims valid and available at the start of the search.																										
<table border="1"> <tr> <td>Place of search</td> <td>Date of completion of the search</td> <td>Examiner</td> <td></td> </tr> <tr> <td>MUNICH</td> <td>13 January 2003</td> <td>Montrone, M</td> <td></td> </tr> </table>				Place of search	Date of completion of the search	Examiner		MUNICH	13 January 2003	Montrone, M																	
Place of search	Date of completion of the search	Examiner																									
MUNICH	13 January 2003	Montrone, M																									
<table border="1"> <tr> <td colspan="2">CATEGORY OF CITED DOCUMENTS</td> <td colspan="2"></td> </tr> <tr> <td>X : particularly relevant if taken alone</td> <td colspan="3">T : theory or principle underlying the invention</td> </tr> <tr> <td>Y : particularly relevant if combined with another document of the same category</td> <td colspan="3">E : earlier patent document, but published on, or after the filing date</td> </tr> <tr> <td>A : technological background</td> <td colspan="3">D : document cited in the application</td> </tr> <tr> <td>O : non-written disclosure</td> <td colspan="3">L : document cited for other reasons</td> </tr> <tr> <td>P : intermediate document</td> <td colspan="3">& : member of the same patent family, corresponding document</td> </tr> </table>				CATEGORY OF CITED DOCUMENTS				X : particularly relevant if taken alone	T : theory or principle underlying the invention			Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date			A : technological background	D : document cited in the application			O : non-written disclosure	L : document cited for other reasons			P : intermediate document	& : member of the same patent family, corresponding document		
CATEGORY OF CITED DOCUMENTS																											
X : particularly relevant if taken alone	T : theory or principle underlying the invention																										
Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date																										
A : technological background	D : document cited in the application																										
O : non-written disclosure	L : document cited for other reasons																										
P : intermediate document	& : member of the same patent family, corresponding document																										



DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)								
P, Y	<p>WO 96 01644 A (THORSETT EUGENE D ; ATHENA NEUROSCIENCES INC (US); PLEISS MICHAEL A) 25 January 1996 (1996-01-25)</p> <p>* abstract *</p> <p>* page 4, line 16-24 *</p> <p>* page 8, line 24 - page 9, line 4 *</p> <p>* page 23, line 18 - page 25, line 28 *</p> <p>-----</p>	1-10									
The supplementary search report has been based on the last set of claims valid and available at the start of the search.											
1											
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td><td style="width: 33%;">Date of completion of the search</td><td colspan="2" style="width: 34%;">Examiner</td></tr> <tr> <td>MUNICH</td><td>13 January 2003</td><td colspan="2">Montrone, M</td></tr> </table>				Place of search	Date of completion of the search	Examiner		MUNICH	13 January 2003	Montrone, M	
Place of search	Date of completion of the search	Examiner									
MUNICH	13 January 2003	Montrone, M									
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>											

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 96 94 3512

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

13-01-2003

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9519790	A	27-07-1995	AU	703152 B2	18-03-1999
			AU	1696095 A	08-08-1995
			CA	2182013 A1	27-07-1995
			CN	1140413 A	15-01-1997
			EP	0804237 A1	05-11-1997
			FI	962958 A	24-09-1996
			HU	75129 A2	28-04-1997
			JP	9508272 T	26-08-1997
			NO	963097 A	24-09-1996
			NZ	279730 A	27-04-1998
			PL	315634 A1	25-11-1996
			WO	9519790 A1	27-07-1995
			US	5840299 A	24-11-1998
<hr/>					
WO 9601644	A	25-01-1996	US	6001809 A	14-12-1999
			AU	2964295 A	09-02-1996
			CA	2193508 A1	25-01-1996
			EP	0769958 A1	02-05-1997
			JP	10506608 T	30-06-1998
			WO	9601644 A1	25-01-1996
<hr/>					



P 3.5818 - Patentlaan 2
2280 HV Rijswijk (ZH)
+31 70 340 2040
TX 31651 epo nl
FAX +31 70 340 3016

Europäisches
Patentamt

Zweigstelle
in Den Haag
Recherchen-
abteilung


European
Patent Office

Branch at
The Hague
Search
division

Office européen
des brevets

Département à
La Haye
Division de la
recherche

Bizley, Richard Edward
Hepworth, Lawrence, Bryer & Bizley
Merlin House
Falconry Court
Baker's Lane
Epping
Essex CM16 5DQ
GRANDE BRETAGNE



Datum/Date
28.02.03

L

Zeichen/Ref/Réf. APEP96303	Anmeldung Nr./Application No./Demande n°./Patent Nr./Patent No./Brevet n°. 95908741.2-2401-US9501219
Anmelder/Applicant/Demandeur/Patentinhaber/Proprietor/Titulaire ATHENA NEUROSCIENCES, INC.	

COMMUNICATION

The European Patent Office herewith transmits as an enclosure the European search report for the above-mentioned European patent application.

If applicable, copies of the documents cited in the European search report are attached.

Additional set(s) of copies of the documents cited in the European search report is (are) enclosed as well.



REFUND OF THE SEARCH FEE

If applicable under Article 10 Rules relating to fees, a separate communication from the Receiving Section on the refund of the search fee will be sent later.



DOCUMENTS CONSIDERED TO BE RELEVANT															
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)												
Y	WO 93 15764 A (BIOGEN INC) 19 August 1993 (1993-08-19) * page 6, line 13 - line 29 * ---	1-18	A61K39/395 C07K16/00 C07K16/18 C07K16/28 C07K16/46 C12N5/10 C12N15/13 C12P21/08												
Y	KOLBINGER F ET AL: "HUMANIZATION OF A MOUSE ANTI-HUMAN IGE ANTIBODY: A POTENTIAL THERAPEUTIC FOR IGE-MEDIATED ALLERGIES" PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 6, no. 8, November 1993 (1993-11), pages 971-980, XP000983997 ISSN: 0269-2139 * page 975, left-hand column, paragraph 2 - page 977, left-hand column, paragraph 2; figures 2,3 * ---	1-18													
P, X	WO 94 16094 A (BIOGEN INC) 21 July 1994 (1994-07-21) * page 5, line 35 - page 10, line 26; claims 4-6,8; tables 1,2 * ---	1-18													
T	LEGER O J P ET AL: "HUMANIZATION OF A MOUSE ANTIBODY AGAINST HUMAN ALPHA-4 INTEGRIN: A POTENTIAL THERAPEUTIC FOR THE TREATMENT OF MULTIPLE SCLEROSIS" HUMAN ANTIBODIES, AMSTERDAM, NL, vol. 8, no. 1, 1997, pages 3-16, XP001105510 ISSN: 1093-2607 -----		TECHNICAL FIELDS SEARCHED (Int.Cl.6) C07K												
2	The supplementary search report has been based on the last set of claims valid and available at the start of the search.														
<table border="1"> <tr> <td>Place of search</td> <td>Date of completion of the search</td> <td>Examiner</td> </tr> <tr> <td>MUNICH</td> <td>13 February 2003</td> <td>Lanzrein, M</td> </tr> </table>				Place of search	Date of completion of the search	Examiner	MUNICH	13 February 2003	Lanzrein, M						
Place of search	Date of completion of the search	Examiner													
MUNICH	13 February 2003	Lanzrein, M													
<table border="0"> <tr> <td>CATEGORY OF CITED DOCUMENTS</td> <td>T : theory or principle underlying the invention</td> </tr> <tr> <td>X : particularly relevant if taken alone</td> <td>E : earlier patent document, but published on, or after the filing date</td> </tr> <tr> <td>Y : particularly relevant if combined with another document of the same category</td> <td>D : document cited in the application</td> </tr> <tr> <td>A : technological background</td> <td>L : document cited for other reasons</td> </tr> <tr> <td>O : non-written disclosure</td> <td>& : member of the same patent family, corresponding document</td> </tr> <tr> <td>P : intermediate document</td> <td></td> </tr> </table>				CATEGORY OF CITED DOCUMENTS	T : theory or principle underlying the invention	X : particularly relevant if taken alone	E : earlier patent document, but published on, or after the filing date	Y : particularly relevant if combined with another document of the same category	D : document cited in the application	A : technological background	L : document cited for other reasons	O : non-written disclosure	& : member of the same patent family, corresponding document	P : intermediate document	
CATEGORY OF CITED DOCUMENTS	T : theory or principle underlying the invention														
X : particularly relevant if taken alone	E : earlier patent document, but published on, or after the filing date														
Y : particularly relevant if combined with another document of the same category	D : document cited in the application														
A : technological background	L : document cited for other reasons														
O : non-written disclosure	& : member of the same patent family, corresponding document														
P : intermediate document															

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 95 90 8741

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

13-02-2003

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9315764	A	19-08-1993	AT AU AU CA DE DE DK EP ES GR HK JP WO	151642 T 674302 B2 3605993 A 2129637 A1 69309906 D1 69309906 T2 625912 T3 0625912 A1 2103468 T3 3024041 T3 1007683 A1 7506566 T 9315764 A1	15-05-1997 19-12-1996 03-09-1993 19-08-1993 22-05-1997 06-11-1997 27-10-1997 30-11-1994 16-09-1997 31-10-1997 23-04-1999 20-07-1995 19-08-1993
WO 9416094	A	21-07-1994	AT AU AU CA DE DE DK EP ES GR HK JP NZ SG WO	182625 T 688751 B2 5993694 A 2153692 A1 69419721 D1 69419721 T2 678122 T3 0678122 A1 2137354 T3 3031692 T3 1011031 A1 8507680 T 261259 A 44845 A1 9416094 A2	15-08-1999 19-03-1998 15-08-1994 21-07-1994 02-09-1999 27-04-2000 06-03-2000 25-10-1995 16-12-1999 29-02-2000 28-04-2000 20-08-1996 20-12-1996 19-12-1997 21-07-1994

PATENT COOPERATION TREA.

PCT

NOTIFICATION CONCERNING
SUBMISSION OF PRIORITY DOCUMENTS

(PCT Administrative Instructions, Section 411)

Date of mailing (day/month/year):
07 July 1997 (07.07.97)Applicant's or agent's file reference
15270-14-3PCInternational application No.
PCT/US96/18807International filing date (day/month/year)
21 November 1996 (21.11.96)Priority date (day/month/year)
21 November 1995 (21.11.95)Applicant
ATHENA NEUROSCIENCES, INC. et al

From the INTERNATIONAL BUREAU

To:

LEIBESCHUETZ, Joe
Townsend and Townsend and Crew LLP
Two Embarcadero Center
8th floor
San Francisco, CA 94111-3834
ETATS-UNIS D'AMERIQUE

IMPORTANT NOTIFICATION

The applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to the following application(s):

Priority application No.: 08/561,521 Priority date: 21 Nov 1995 (21.11.95) Priority country: US Date of receipt of priority document: 21 Nov 1996 (21.11.96)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

R. Raissi

Telephone No.: (41-22) 338.83.38

PENT COOPERATION TREA.

PCT

NOTIFICATION CONCERNING
DOCUMENT TRANSMITTED

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as designated Office

Date of mailing (day/month/year)
07 July 1997 (07.07.97)

International application No.
PCT/US96/18807

International filing date (day/month/year)
21 November 1996 (21.11.96)

Applicant

ATHENA NEUROSCIENCES, INC. et al

The International Bureau transmits herewith the following documents and number thereof:

cop(ies) of priority document(s) (Rule 17.2(a))

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

R. Raissi

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 15 July 1997 (15.07.97)	Applicant's or agent's file reference 15270-14-3PC
International application No. PCT/US96/18807	Priority date (day/month/year) 21 November 1995 (21.11.95)
International filing date (day/month/year) 21 November 1996 (21.11.96)	Applicant BENDIG, Mary, M. et al

1. The designated Office is hereby notified of its election made:

 in the demand filed with the International Preliminary Examining Authority on:

10 June 1997 (10.06.97)

 in a notice effecting later election filed with the International Bureau on:2. The election was was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Martine Lee Telephone No.: (41-22) 338.83.38
---	---

PATENT COOPERATION TREATY

PCT

20


REC'D	16 JAN 1998
WIPO	PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 15270-1430PC	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US96/18807	International filing date (day/month/year) 21 NOVEMBER 1996	Priority date (day/month/year) 21 NOVEMBER 1995
International Patent Classification (IPC) or national classification and IPC IPC(6): A61K 39/395 and US Cl.: 424/130.1, 133.1, 141.1, 143.1, 144.1, 153.1, 154.1, 173.1		
Applicant ATHENA NEUROSCIENCES, INC.		

<ol style="list-style-type: none"> 1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36. 2. This REPORT consists of a total of <u>4</u> sheets. <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of <u>—</u> sheets.</p>
<ol style="list-style-type: none"> 3. This report contains indications relating to the following items: <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of report with regard to novelty, inventive step or industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application

Date of submission of the demand 10 JUNE 1997	Date of completion of this report 15 DECEMBER 1997
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer PHILIP GAMBEL 
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US96/18807

I. Basis of the report

1. This report has been drawn on the basis of (Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments):

the international application as originally filed.

the description, pages 1-84, as originally filed.

pages NONE, filed with the demand.

pages NONE, filed with the letter of _____.

pages , filed with the letter of _____.

the claims, Nos. 1-26, as originally filed.

Nos. NONE, as amended under Article 19.

Nos. NONE, filed with the demand.

Nos. NONE, filed with the letter of _____.

Nos. , filed with the letter of _____.

the drawings, sheets/fig 1-16, as originally filed.

sheets/fig NONE, filed with the demand.

sheets/fig NONE, filed with the letter of _____.

sheets/fig , filed with the letter of _____.

2. The amendments have resulted in the cancellation of:

the description, pages NONE.

the claims, Nos. NONE.

the drawings, sheets/fig NONE.

3. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the ~~Supplemental Box~~ Additional observations below (Rule 70.2(c)).

4. Additional observations, if necessary:

NONE

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. STATEMENT**

Novelty (N)	Claims <u>1-26</u>	YES
	Claims <u>NONE</u>	NO
Inventive Step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-26</u>	NO
Industrial Applicability (IA)	Claims <u>1-26</u>	YES
	Claims <u>NONE</u>	NO

2. CITATIONS AND EXPLANATIONS

Claims 1-26 lack an inventive step under PCT Article 33(3) as being obvious over Monshizadegan et al. (Agents Actions, 1993) or Wayner (WO 91/03252) in view of Protein Design Labs, Inc. (WO 90/07861) and Kettleborough et al. (Protein Engineering, 1991. The instant claims are drawn to humanized 21-6 VLA-4-specific antibodies, nucleic acids that encode these proteins as well as their use in diagnostic and therapeutic methods.

Monshizadegan et al. teach the 21-6 VLA-4-specific antibody and its ability to inhibit $\alpha 4$ integrin function of the instant invention (see entire document). It is noted that this was presented at the Sixth International Conference of The Inflammation Research Association. This reference differs from the instant claims by not teaching the humanization of the 21-6 monoclonal antibody.

Wayner et al. teach deriving $\alpha 4\beta 1$ -specific antibodies for various in vitro and in vivo diagnostic and therapeutic utilities, which are encompassed by the claims (see entire document). Since the $\alpha 4\beta 1$ -specificity is the same as VLA-4, it is not clear what critical differences exist between the claimed and referenced antibodies. Wayner et al. differs from the instant claims by not teaching the humanization of antibodies per se.

Both Protein Design Labs, Inc. and Kettleborough et al. teach the art-known and claimed procedures to humanize a monoclonal antibody, including the appropriate vectors, nucleic acids, modelling procedures and computers that achieve appropriate specificity and affinity for diagnostic and therapeutic uses (see entire documents). Here, the art-known advantage of humanizing antibodies for reducing immunogenicity of murine antibodies and providing human immunoglobulin effector function was stated. These references teach that humanized antibodies have a wide variety of utilities in vitro, such as cell typing (e.g. diagnosis) and isolating cells. Therefore, the ordinary artisan would have humanized the VLA-4-specific humanized antibodies for both in vitro as well as in vivo (Continued on Supplemental Sheet.)

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

**V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):
purposes.**

Although the references are silent about the exact sequences of the VLA-4-specific antibodies and the human antibodies, the recombinant techniques and computer analyses of CDR grafting as taught by the references would have resulted in the same or very nearly the same structural and functional characteristics of the instant claims since both the references and instant invention use the same techniques, the same antibody specificities and the same goals. The claimed functional limitations encompassed by the claims would be expected properties of selecting for VLA-4-specific antibodies to specifically bind and inhibit VLA-4, including the generation of humanized immunoglobulins with/without certain effector functions depending upon the condition targeted. The claims drawn to specifically defined immunoglobulin specificities are obvious since the record does not contain any evidence that the cell lines differ in any significant manner or produce monoclonal antibodies that differ in any significant aspect from VLA-4-specific antibodies that one of ordinary skill in the art would expect to generate using VLA-4 as the starting antigen in the basic method of generating antibodies and humanizing said antibodies. There appears no evidence that the use of various sources of framework amino acids would differ in an unexpected or distinct manner from those available to the ordinary artisan at the time the invention was made.

One of ordinary skill in the art at the time the invention was made would have been motivated to select and evaluate the efficacy of humanizing VLA-4-specific antibodies including the 21-6 monoclonal antibody as a diagnostic and therapeutic tool in treating human disease. From the teachings of the references, it was apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

----- NEW CITATIONS -----

NONE

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 15270-14-3PC	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US96/18807	International filing date (day/month/year) 21 NOVEMBER 1996	(Earliest) Priority Date (day/month/year) 21 NOVEMBER 1995 ✓
Applicant ATHENA NEUROSCIENCES, INC.		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 2 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

1. Certain claims were found unsearchable (See Box I).
2. Unity of invention is lacking (See Box II).
3. The international application contains disclosure of a nucleotide and/or amino acid sequence listing and the international search was carried out on the basis of the sequence listing
 - filed with the international application.
 - furnished by the applicant separately from the international application,
 - but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.
 - transcribed by this Authority.
4. With regard to the title, the text is approved as submitted by the applicant.
 - the text has been established by this Authority to read as follows:
5. With regard to the abstract,
 - the text is approved as submitted by the applicant.
 - the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. The figure of the drawings to be published with the abstract is:

Figure No. _____

 - as suggested by the applicant.
 - because the applicant failed to suggest a figure.
 - because this figure better characterizes the invention.

None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/18307

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 39/395

US CL :424/130.1, 133.1, 141.1, 143.1, 144.1, 153.1, 154.1, 173.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/130.1, 133.1, 141.1, 143.1, 144.1, 153.1, 154.1, 173.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG, BIOSIS, CA, EMBASE, MEDLINE, WPI
search term: alpha-4-integrin, 21-6, 21/28'cl, inflammation

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y ✓	Agents Actions, Volume 39, issued 1993, Monshizadegan et al., "VLA-4-Dependent Adhesion Activities of U937 Cells and Guinea Pig Bronchoalveolar Lavage Leukocytes", pages C177-C179, see entire document.	1-26
Y ✓	WO, A, 91/03252 (WAYNER) 21 March 1991, see entire document.	1-26
Y ✓	WO, A, 90/07861 (PROTEIN DESIGN LABS, INC.) 26 July 1990, see entire document.	1-26
Y ✓	Protein Engineering, Volume 4, Number 7, issued 1991, Kettleborough et al., "Humanization of a Mouse Monoclonal Antibody by CDR-Grafting the Importance of Framework Residues on Loop Conformation", pages 773-783, see entire document.	1-26

 Further documents are listed in the continuation of Box C. See patent family annex.

• Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

25 FEBRUARY 1997

Date of mailing of the international search report

18 MAR 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PHILLIP GAMBEL

Telephone No. (703) 308-0196



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/395		A1	(11) International Publication Number: WO 97/18838
(21) International Application Number: PCT/US96/18807		(43) International Publication Date: 29 May 1997 (29.05.97)	
(22) International Filing Date: 21 November 1996 (21.11.96)		(74) Agents: LEIBESCHUETZ, Joe et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th floor, San Francisco, CA 94111-3834 (US).	
(30) Priority Data: 08/561,521 21 November 1995 (21.11.95) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(60) Parent Application or Grant (63) Related by Continuation US 08/561,521 (CIP) Filed on 21 November 1995 (21.11.95)		(71) Applicant (for all designated States except US): ATHENA NEUROSCIENCES, INC. [US/US]; 800 Gateway Boulevard, South San Francisco, CA 94080 (US).	
(72) Inventors; and (75) Inventors/Applicants (for US only): BENDIG, Mary, M. [US/GB]; 64 Solent Road, West Hampstead NW6 1TX (GB). LEGER, Olivier, J. [FR/GB]; 24 Moxon Street, Hertfordshire EN5 5T5 (GB). SALDANHA, Jose [GB/GB]; 22A Lincoln Way, Enfield, Middlesex EN5 5T5 (GB). JONES, S., Tarren [GB/GB]; 10 The Close, Radlett, Hertfordshire WD7 8HA (GB). YEDNOCK, Ted, A. [US/US]; 46 Crest Road, Fairfax, CA 94930 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN

(57) Abstract

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN

5

CROSSREFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of USSN
08/561,521, filed November 21, 1995, which is incorporated by
reference in their entirety for all purposes.

TECHNICAL FIELD

This invention relates generally to humanized antibodies specific for the alpha-4 ($\alpha 4$) integrin and therapeutic uses of the same.

BACKGROUND OF THE INVENTION

20 Inflammation is a response of vascularized tissues to
infection or injury and is effected by adhesion of leukocytes
to the endothelial cells of blood vessels and their
infiltration into the surrounding tissues. In normal
inflammation, the infiltrating leukocytes release toxic
mediators to kill invading organisms, phagocytize debris and
25 dead cells, and play a role in tissue repair and the immune
response. However, in pathologic inflammation, infiltrating
leukocytes are over-responsive and can cause serious or fatal
damage. See, e.g., Hickey, *Psychoneuroimmunology II* (Academic
Press 1990).

30 The attachment of leukocytes to endothelial cells is
effected via specific interaction of cell-surface ligands and
receptors on endothelial cells and leukocytes. See generally
Springer, *Nature* 346:425-433 (1990). The identity of the
ligands and receptors varies for different cell subtypes,
35 anatomical locations and inflammatory stimuli. The VLA-4
leukocyte cell-surface receptor was first identified by Hemler,
EP 330,506 (1989) (incorporated by reference in its entirety
for all purposes). VLA-4 is a member of the $\beta 1$ integrin family
of cell surface receptors, each of which comprises α and β

chains. VLA-4 contains an $\alpha 4$ chain and a $\beta 1$ chain. VLA-4 specifically binds to an endothelial cell ligand termed VCAM-1. See Elices et al., *Cell* 60:577-584 (1990) (incorporated by reference in its entirety for all purposes). The $\alpha 4$ chain also associates with a $\beta 7$ chain to form an integrin referred to as $\alpha 4\beta 7$. Although VCAM-1 was first detected on activated human umbilical vein cells, this ligand has also been detected on brain endothelial cells. See commonly owned, co-pending application US Serial No. 07/871,223 (incorporated by reference in its entirety for all purposes).

Adhesion molecules such as $\alpha 4$ integrin are potential targets for therapeutic agents. The VLA-4 receptor of which $\alpha 4$ integrin is a subunit is a particularly important target because of its interaction with a ligand residing on brain endothelial cells. Diseases and conditions resulting from brain inflammation have particularly severe consequences. For example, one such disease, multiple sclerosis (MS), has a chronic course (with or without exacerbations and remissions) leading to severe disability and death. The disease affects an estimated 250,000 to 350,000 people in the United States alone.

Antibodies against $\alpha 4$ integrin have been tested for their anti-inflammatory potential both *in vitro* and *in vivo* in animal models. See USSN 07/871,223 and Yednock et al., *Nature* 356:63-66 (1992) (incorporated by reference in its entirety for all purposes). The *in vitro* experiments demonstrate that $\alpha 4$ integrin antibodies block attachment of lymphocytes to brain endothelial cells. The animal experiments test the effect of $\alpha 4$ integrin antibodies on animals having an artificially induced condition (experimental autoimmune encephalomyelitis), simulating multiple sclerosis. The experiments show that administration of anti- $\alpha 4$ integrin antibodies prevents inflammation of the brain and subsequent paralysis in the animals. Collectively, these experiments identify anti- $\alpha 4$ integrin antibodies as potentially useful therapeutic agents for treating multiple sclerosis and other inflammatory diseases and disorders.

A significant problem with the anti- $\alpha 4$ integrin antibodies available to-date is that they are all of murine origin, and

therefore likely to raise a human anti-mouse response (HAMA) in clinical use. A HAMA response reduces the efficacy of mouse antibodies in patients and prevents continued administration. One approach to this problem is to humanize mouse antibodies.

5 In this approach, complementarity determining regions (CDRs) and certain other amino acids from donor mouse variable regions are grafted into human variable acceptor regions and then joined to human constant regions. See, e.g., Riechmann et al., *Nature* 332:323-327 (1988); Winter, US 5,225,539 (1993) (each of
10 which is incorporated by reference in its entirety for all purposes).

Although several examples of humanized antibodies have been produced, the transition from a murine to a humanized antibody involves a compromise of competing considerations, the
15 solution of which varies with different antibodies. To minimize immunogenicity, the immunoglobulin should retain as much of the human acceptor sequence as possible. However, to retain authentic binding properties, the immunoglobulin framework should contain sufficient substitutions of the human
20 acceptor sequence to ensure a three-dimensional conformation of CDR regions as close as possible to that in the original mouse donor immunoglobulin. As a result of these competing considerations, many humanized antibodies produced to-date show some loss of binding affinity compared with the corresponding
25 murine antibodies from which they are derived. See, e.g., Jones et al., *Nature* 321:522-525 (1986); Shearman et al., *J. Immunol.* 147:4366-4373 (1991); Kettleborough et al., *Protein Engineering* 4:773-783 (1991); Gorman et al., *Proc. Natl. Acad. Sci. USA* 88:4181-4185 (1991); Tempest et al., *Biotechnology*
30 9:266-271 (1991).

Based on the foregoing it is apparent that a need exists for humanized anti- $\alpha 4$ integrin antibodies demonstrating a strong affinity for $\alpha 4$ integrin, while exhibiting little, if any, human-antimouse response. The present invention fulfill
35 this and other needs.

SUMMARY OF THE INVENTION

The invention provides uses of a humanized antibody to alpha-4 integrin in the manufacture of a medicament for treating a disease selected from the group consisting of 5 asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.

10 The humanized immunoglobulins used in the above methods specifically bind to a alpha-4 integrin. The humanized antibodies comprise a humanized light chain and a humanized heavy chain. A preferred humanized light chain comprises three complementarity determining regions (CDR1, CDR2 and CDR3) 15 having amino acid sequences from the corresponding complementarity determining regions of a mouse 21-6 immunoglobulin light chain, and a variable region framework from a human kappa light chain variable region framework sequence except in at least one position selected from a first 20 group consisting of positions L45, L49, L58 and L69, wherein the amino acid position is occupied by the same amino acid present in the equivalent position of the mouse 21.6 immunoglobulin light chain variable region framework. A preferred humanized heavy chain comprises three complementarity 25 determining regions (CDR1, CDR2 and CDR3) having amino acid sequences from the corresponding complementarity determining regions of a mouse 21-6 immunoglobulin heavy chain, and a variable region framework from a human heavy chain variable region framework sequence except in at least one position 30 selected from a group consisting of H27, H28, H29, H30, H44, H71, wherein the amino acid position is occupied by the same amino acid present in the equivalent position of the mouse 21-6 immunoglobulin heavy chain variable region framework. The immunoglobulins specifically bind to alpha-4 integrin with an 35 affinity having a lower limit of about 10^7 M⁻¹ and an upper limit of about five times the affinity of the mouse 21-6 immunoglobulin.

Usually, the humanized light and heavy chain variable region frameworks are from RE1 and 21/28'CL variable region framework sequences respectively. When the humanized light chain variable region framework is from RE1, at least two framework amino acids are replaced. One amino acid is from the first group of positions described *supra*. The other amino acids is from a third group consisting of positions L104, L105 and L107. This position is occupied by the same amino acid present in the equivalent position of a kappa light chain from a human immunoglobulin other than RE1.

Some humanized immunoglobulins have a mature light chain variable region sequence designated La or Lb in Figure 6, or a mature heavy chain variable region sequence designated Ha, Hb or Hc in Figure 7. Preferred humanized immunoglobulins include those having an La light chain and an Ha, Hb or Hc heavy chain.

In another aspect the invention provides pharmaceutical compositions for use in treating the above diseases. The pharmaceutical compositions comprise a humanized immunoglobulin or binding fragment as described *supra*, and a pharmaceutically acceptable carrier. In some methods of treatment a therapeutically effective amount of a pharmaceutical composition is administered to a patient suffering from one of the diseases listed above.

25

BRIEF DESCRIPTION OF FIGURES

Figure 1: DNA (SEQ. ID NO:1) and amino acid (SEQ. ID NO:2) sequences of the mouse 21.6 light chain variable region.

Figure 2: DNA (SEQ. ID NO:3) and amino acid (SEQ. ID NO:4) sequences of the mouse 21.6 heavy chain variable region.

30

Figure 3: Light (A) and heavy (B) chain expression vectors used to produce chimeric and reshaped human antibodies with human kappa light chains and human gamma-1 heavy chains in mammalian cells.

35

Figure 4: ELISA comparison of chimeric and mouse 21.6 antibody binding to L cells expressing human $\alpha 4\beta 1$ integrin on their surface.

Figure 5: Molecular model of the variable regions of mouse 21.6 antibody. Residues of special interest are labelled.

Figure 6: Comparisons of the amino acid sequences of mouse and reshaped human 21.6 (SEQ. ID NO:5) light chain variable regions. The amino acid residues that are part of the Chothia canonical sequences for the CDR loop structures are marked with an asterisk. REI (SEQ. ID NO:6) shows the FRs and CDRs from the V_L region of human REI light chain. La (SEQ. ID NO:7) and Lb (SEQ. ID NO:8) are the two versions of reshaped human 21.6 V_L region. The residues in the FRs of La that differ from those in the REI sequence are underlined. In Lb, only the residues in the framework regions that differ from those of REI are shown.

Figure 7: Comparisons of the amino acid sequences of the mouse and reshaped human 21.6 (SEQ. ID NO:9) heavy chain variable regions. The amino acid residues that are part of the canonical sequences for the Chothia CDR loop structures are marked with an asterisk. 2*CL (SEQ. ID NO:10) shows the FRs and CDRs from the V_H region of human 21/28'CL antibody. Ha (SEQ. ID NO:11), Hb (SEQ. ID NO:12), and Hc (SEQ. ID NO:13) are the three versions of reshaped human 21.6 V_H region. The residues in the FRs of Ha that differ from those in the 21/28'CL sequence are underlined. In Hb and Hc, only the residues in the framework regions that differ from those of 21/28'CL are shown.

Figure 8: PCR-based construction of version "a" of reshaped human 21.6 light chain variable region. The dotted lines indicate a complementary sequence of at least 21 bases between the primers.

Figure 9: PCR-based construction of version "a" of reshaped human 21.6 heavy chain variable region.

Figure 10: cDNA and amino acid sequences (SEQ. ID NOS: 14 and 15) of the first version ("a") of reshaped human 21.6 light chain variable region.

Figure 11: DNA and amino acid sequences (SEQ. ID NOS: 16 and 17) of the first version ("a") of reshaped human 21.6 heavy chain variable region.

Figure 12: ELISA comparison of chimeric and reshaped human 21.6 antibodies to bind to L cells expressing human $\alpha 4\beta 1$ integrin on their surface.

Figure 13: Comparison of mouse 21.6 antibody with a different anti-alpha-4 integrin antibody, L25. Panel A compares the ability of the antibodies to block binding of U937 monocytic cells to purified VCA-1 in the presence and absence of Mn^{2+} . Panel B compares the ability of the antibodies to block binding of Jurkat cells to increasing concentrations of VCAM-1.

Figure 14: Delay of weight loss in animals treated with mouse or human 21.6 antibody.

Figure 15: Reversal of clinical symptoms in animals treated with mouse or human 21.6 antibody.

Figure 16: Reversal of weight loss in animals treated with mouse or human 21.6 antibody.

DEFINITIONS

Abbreviations for the twenty naturally occurring amino acids follow conventional usage (*Immunology - A Synthesis* (2nd ed., E.S. Golub & D.R. Gren, eds., Sinauer Associates, Sunderland, MA, 1991)). Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as α,α -disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylsine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, ω -N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). Moreover, amino acids may be modified by glycosylation, phosphorylation and the like.

In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the righthand direction is the carboxy-terminal direction, in accordance with standard usage and convention. Similarly, unless specified otherwise, the lefthand end of single-stranded polynucleotide

sequences is the 5' end; the lefthand direction of double-stranded polynucleotide sequences is referred to as the 5' direction. The direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction; 5 sequence regions on the DNA strand having the same sequence as the RNA and which are 5' to the 5' end of the RNA transcript are referred to as "upstream sequences"; sequence regions on the DNA strand having the same sequence as the RNA and which are 3' to the 3' end of the RNA transcript are referred to as 10 "downstream sequences."

The phrase "polynucleotide sequence" refers to a single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. It includes self-replicating plasmids, infectious polymers of DNA 15 or RNA and non-functional DNA or RNA.

The following terms are used to describe the sequence relationships between two or more polynucleotides: "reference sequence", "comparison window", "sequence identity", "percentage of sequence identity", and "substantial identity". 20 A "reference sequence" is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger sequence, for example, as a segment of a full-length cDNA or gene sequence given in a sequence listing, such as a polynucleotide sequence of Figs. 1 or 2, or may comprise a 25 complete DNA or gene sequence. Generally, a reference sequence is at least 20 nucleotides in length, frequently at least 25 nucleotides in length, and often at least 50 nucleotides in length. Since two polynucleotides may each (1) comprise a sequence (i.e., a portion of the complete polynucleotide 30 sequence) that is similar between the two polynucleotides, and (2) may further comprise a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" 35 to identify and compare local regions of sequence similarity. A "comparison window", as used herein, refers to a conceptual segment of at least 20 contiguous nucleotide positions wherein a polynucleotide sequence may be compared to a reference

sequence of at least 20 contiguous nucleotides and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less as compared to the reference sequence (which does not 5 comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. 10 Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Natl. Acad. Sci. (USA)* 85:2444 (1988) (each of which is incorporated by reference in its entirety for all purposes), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the 15 Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, WI), or by inspection, and the best alignment (i.e., resulting in the highest percentage of sequence similarity over the comparison window) generated by the various methods is selected. The term 20 "sequence identity" means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over the window of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number 25 of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to 30 yield the percentage of sequence identity. The terms "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence 35 identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison window of at least 20 nucleotide positions, frequently over a window of at least 25-50 nucleotides, wherein the percentage of sequence

identity is calculated by comparing the reference sequence to the polynucleotide sequence which may include deletions or additions over the window of comparison. The reference sequence may be a subset of a larger sequence, for example, the sequence shown in Figs. 1 or 2.

As applied to polypeptides, the term "sequence identity" means peptides share identical amino acids at corresponding positions. The term "sequence similarity" means peptides have identical or similar amino acids at corresponding positions. The term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80 percent sequence identity, more preferably at least 95 percent sequence identity or more (e.g., 99 percent sequence identity). Preferably, residue positions which are not identical differ by conservative amino acid substitutions. The term "substantial similarity" means that two peptide sequences share corresponding percentages of sequence similarity.

The term "substantially pure" means an object species is more abundant than any other individual species in the composition, and preferably a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition will comprise more than about 80 to 90 percent of all macromolecular species present in the composition. Most preferably, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.

For purposes of classifying amino acids substitutions as conservative or nonconservative, amino acids are grouped as follows: Group I (hydrophobic sidechains): norleucine, met,

ala, val, leu, ile; Group II (neutral hydrophilic side chains): cys, ser, thr; Group III (acidic side chains): asp, glu; Group IV (basic side chains): asn, gln, his, lys, arg; Group V (residues influencing chain orientation): gly, pro; and 5 Group VI (aromatic side chains): trp, tyr, phe. Conservative substitutions involve substitutions between amino acids in the same class. Non-conservative substitutions constitute exchanging a member of one of these classes for another.

Amino acids from the variable regions of the mature heavy 10 and light chains of immunoglobulins are designated Hx and Lxx respectively, where x is a number designating the position of an amino acids according to the scheme of Kabat et al., *Sequences of Proteins of Immunological Interest* (National Institutes of Health, Bethesda, MD (1987) and (1991)) 15 (hereinafter collectively referred to as "Kabat et al.," incorporated by reference in their entirety for all purposes). Kabat et al. list many amino acid sequences for antibodies for each subclass, and list the most commonly occurring amino acid for each residue position in that subclass. Kabat et al. use a 20 method for assigning a residue number to each amino acid in a listed sequence, and this method for assigning residue numbers has become standard in the field. Kabat et al.'s scheme is extendible to other antibodies not included in the compendium by aligning the antibody in question with one of the consensus 25 sequences in Kabat et al. The use of the Kabat et al. numbering system readily identifies amino acids at equivalent positions in different antibodies. For example, an amino acid at the L50 position of a human antibody occupies the equivalence position to an amino acid position L50 of a mouse 30 antibody.

DETAILED DESCRIPTION

I. Humanized Antibodies Specific for alpha-4 integrin

In one embodiment of the invention, humanized 35 immunoglobulins (or antibodies) specific for the alpha-4 integrin, a subunit of VLA-4 are provided. The humanized immunoglobulins have variable framework regions substantially from a human immunoglobulin (termed an acceptor immunoglobulin)

and complementarity determining regions substantially from a mouse immunoglobulin termed mu MAb 21.6 (referred to as the donor immunoglobulin). The constant region(s), if present, are also substantially from a human immunoglobulin. The humanized 5 antibodies exhibit a specific binding affinity for alpha-4 integrin of at least 10^7 , 10^8 , 10^9 , or 10^{10} M^{-1} . Usually the upper limit of binding affinity of the humanized antibodies for alpha-4 integrin is within a factor of three or five of that of mu MAb 21.6 (about 10^9 M^{-1}). Often the lower limit of binding 10 affinity is also within a factor of three or five of that of mu MAb 21.6.

A. General Characteristics of Immunoglobulins

The basic antibody structural unit is known to comprise a 15 tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen 20 recognition. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.

Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or 25 epsilon, and define the antibody's isotype as IgG, IgM, IgA, IgD and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids. (See 30 generally, *Fundamental Immunology* (Paul, W., ed., 2nd ed. Raven Press, N.Y., 1989), Ch. 7 (incorporated by reference in its entirety for all purposes)).

The variable regions of each light/heavy chain pair form 35 the antibody binding site. The chains all exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair are aligned by the framework regions,

enabling binding to a specific epitope. CDR and FR residues are delineated according to the standard sequence definition of Kabat et al., *supra*. An alternative structural definition has been proposed by Chothia et al., *J. Mol. Biol.* 196:901-917
5 (1987); *Nature* 342:878-883 (1989); and *J. Mol. Biol.* 186:651-
663 (1989) (hereinafter collectively referred to as "Chothia et
al." and incorporated by reference in their entirety for all
purposes). When framework positions, as defined by Kabat et
al., *supra*, that constitute structural loop positions as
10 defined by Chothia et al., *supra*, the amino acids present in
the mouse antibody are usually incorporated into the humanized
antibody.

B. Production of Humanized Antibodies

(1) Mouse MAb 21.6

15 The starting material for production of humanized antibodies is mu MAb 21.6. The isolation and properties of this antibody are described in USSN 07/871,223. Briefly, mu MAb 21.6 is specific for the alpha-4 integrin and has been
20 shown to inhibit human lymphocyte binding to tissue cultures of rat brain cells stimulated with tumor necrosis factor. The cloning and sequencing of cDNA encoding the mu MAb 21.6 antibody heavy and light chain variable regions is described in Example 1, and the nucleotide and predicted amino acids
25 sequences are shown in Figures 1 and 2. These figures also illustrate the subdivision of the amino acid coding sequencing into framework and complementarity determining domains. From N-terminal to C-terminal, both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The
30 assignment of amino acids to each domain is in accordance with the numbering convention of Kabat et al., *supra*.

(2) Selection of Human Antibodies to Supply Framework Residues

35 The substitution of mouse CDRs into a human variable domain framework is most likely to result in retention of their correct spatial orientation if the human variable domain framework adopts the same or similar conformation to the mouse

variable framework from which the CDRs originated. This is achieved by obtaining the human variable domains from human antibodies whose framework sequences exhibit a high degree of sequence identity with the murine variable framework domains 5 from which the CDRs were derived. The heavy and light chain variable framework regions can be derived from the same or different human antibody sequences. The human antibody sequences can be the sequences of naturally occurring human antibodies or can be consensus sequences of several human 10 antibodies. See Kettleborough et al., *Protein Engineering* 4:773 (1991); Kolbinger et al., *Protein Engineering* 6:971 (1993).

Suitable human antibody sequences are identified by computer comparisons of the amino acid sequences of the mouse 15 variable regions with the sequences of known human antibodies. The comparison is performed separately for heavy and light chains but the principles are similar for each. This comparison reveals that the mu 21.6 light chain shows greatest sequence identity to human light chains of subtype kappa 1, and 20 that the mu 21.6 heavy chain shows greatest sequence identity to human heavy chains of subtype one, as defined by Kabat et al., *supra*. Thus, light and heavy human framework regions are usually derived from human antibodies of these subtypes, or from consensus sequences of such subtypes. The preferred light 25 and heavy chain human variable regions showing greatest sequence identity to the corresponding regions from mu MAb 21.6 are from antibodies RE1 and 21/28'CL respectively.

(3) Computer Modelling

30 The unnatural juxtaposition of murine CDR regions with human variable framework region can result in unnatural conformational restraints, which, unless corrected by substitution of certain amino acid residues, lead to loss of binding affinity. The selection of amino acid residues for 35 substitution is determined, in part, by computer modelling. Computer hardware and software for producing three-dimensional images of immunoglobulin molecules are widely available. In general, molecular models are produced starting from solved

structures for immunoglobulin chains or domains thereof. The chains to be modelled are compared for amino acid sequence similarity with chains or domains of solved three dimensional structures, and the chains or domains showing the greatest sequence similarity is/are selected as starting points for construction of the molecular model. For example, for the light chain of mu MAb 21.6, the starting point for modelling the framework regions, CDR1 and CDR2 regions, was the human light chain RE1. For the CDR3 region, the starting point was the CDR3 region from the light chain of a different human antibody HyHEL-5. The solved starting structures are modified to allow for differences between the actual amino acids in the immunoglobulin chains or domains being modelled, and those in the starting structure. The modified structures are then assembled into a composite immunoglobulin. Finally, the model is refined by energy minimization and by verifying that all atoms are within appropriate distances from one another and that bond lengths and angles are within chemically acceptable limits. Example 4 discusses in more detail the steps taken to produce a three dimensional computer model for the variable regions of the mu MAb 21.6, and the model is shown in Figure 5. This model can in turn serve as a starting point for predicting the three-dimensional structure of an antibody containing the mu MAb 21.6 complementarity determining regions substituted in human framework structures. Additional models can be constructed representing the structure when further amino acid substitutions to be discussed *infra*, are introduced.

(4) Substitution of Amino Acid Residues

As noted *supra*, the humanized antibodies of the invention comprise variable framework regions substantially from a human immunoglobulin and complementarity determining regions substantially from a mouse immunoglobulin termed mu MAb 21.6. Having identified the complementarity determining regions of mu MAb 21.6 and appropriate human acceptor immunoglobulins, the next step is to determine which, if any, residues from these components should be substituted to optimize the properties of the resulting humanized antibody. In general, substitution of

human amino acid residues with murine should be minimized, because introduction of murine residues increases the risk of the antibody eliciting a HAMA response in humans. Amino acids are selected for substitution based on their possible influence 5 on CDR conformation and/or binding to antigen. Investigation of such possible influences is by modelling, examination of the characteristics of the amino acids at particular locations, or empirical observation of the effects of substitution or mutagenesis of particular amino acids.

10 When an amino acid differs between a mu MAb 21.6 variable framework region and an equivalent human variable framework region, the human framework amino acid should usually be substituted by the equivalent mouse amino acid if it is reasonably expected that the amino acid:

15 (1) noncovalently binds antigen directly (e.g., amino acids at positions L49, L69 of mu MAb 21.6),

(2) is adjacent to a CDR region, is part of a CDR region under the alternative definition proposed by Chothia et al., *supra*, or otherwise interacts with a CDR region (e.g., is 20 within about 3Å of a CDR region) (e.g., amino acids at positions L45, L58, H27, H28, H29, H30 and H71 of mu MAb 21.6), or

(3) participates in the V_L - V_H interface (e.g., amino acids at position H44 of mu MAb 21.6).

25 Other candidates for substitution are acceptor human framework amino acids that are unusual for a human immunoglobulin at that position (e.g., amino acids at positions L104, L105 and L107 of mu MAb 21.6). These amino acids can be substituted with amino acids from the equivalent position of 30 more typical human immunoglobulins. Alternatively, amino acids from equivalent positions in the mouse MAb 21.6 can be introduced into the human framework regions when such amino acids are typical of human immunoglobulin at the equivalent positions.

35 In general, substitution of all or most of the amino acids fulfilling the above criteria is desirable. Occasionally, however, there is some ambiguity about whether a particular amino acid meets the above criteria, and alternative variant

immunoglobulins are produced, one of which has that particular substitution, the other of which does not. The humanized antibodies of the present invention will usually contain a substitution of a human light chain framework residue in at least 17
5 more usually 4, of the following positions: L45, L49, L58 and L69. The humanized antibodies also usually contain a substitution 10 of a human heavy chain framework residue with a least 1, 2, 3, 4, or 5, and sometimes 6, of the following positions: L27, H28, H29, H30, H44 and H71. Optionally, H36 may also be substituted. In preferred embodiments when the human light chain acceptor immunoglobulin is RE1, the light chain also contains substitutions in at least 1 or 2, and more 15 usually 3, of the following positions: L104, L105 and L107. These positions are substituted with the amino acid from the equivalent position of a human immunoglobulin having a more typical amino acid residues. Appropriate amino acids to 20 substitute are shown in Figures 6 and 7.
Usually the CDR regions in humanized antibodies are substantially identical, and more usually, identical to the corresponding CDR regions in the mu MAb 21.6 antibody. Occasionally, however, it is desirable to change one of the residues in a CDR region. For example, Example 5 identifies an amino acid similarity between the mu MAb 21.6 CDR3 and the 25 VCAM-1 ligand. This observation suggests that the binding affinity of humanized antibodies might be improved by redesigning the heavy chain CDR3 and the CDR3 domain can be substituted with amino acids from the 30 binding domain. Accordingly, one or more amino acids from the sometimes possible to make one or more conservative amino acid substitutions of CDR residues without appreciably affecting the binding affinity of the resulting humanized immunoglobulin. Other than for the specific amino acid substitutions 35 discussed above, the framework regions of humanized immunoglobulins are usually substantially identical, and more usually, identical to the framework regions of the human antibodies from which they were derived. Of course, many of

the amino acids in the framework region make little or no direct contribution to the specificity or affinity of an antibody. Thus, many individual conservative substitutions of framework residues can be tolerated without appreciable change 5 of the specificity or affinity of the resulting humanized immunoglobulin. However, in general, such substitutions are undesirable.

(5) Production of Variable Regions

Having conceptually selected the CDR and framework 10 components of humanized immunoglobulins, a variety of methods are available for producing such immunoglobulins. Because of the degeneracy of the code, a variety of nucleic acid sequences will encode each immunoglobulin amino acid sequence. The 15 desired nucleic acid sequences can be produced by *de novo* solid-phase DNA synthesis or by PCR mutagenesis of an earlier prepared variant of the desired polynucleotide. Oligonucleotide-mediated mutagenesis is a preferred method for preparing substitution, deletion and insertion variants of 20 target polypeptide DNA. See Adelman et al., *DNA* 2:183 (1983). Briefly, the target polypeptide DNA is altered by hybridizing an oligonucleotide encoding the desired mutation to a single-stranded DNA template. After hybridization, a DNA polymerase 25 is used to synthesize an entire second complementary strand of the template that incorporates the oligonucleotide primer, and encodes the selected alteration in the target polypeptide DNA.

(6) Selection of Constant Region

The variable segments of humanized antibodies produced as 30 described *supra* are typically linked to at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. Human constant region DNA sequences can be isolated in accordance with well-known procedures from a variety of human cells, but preferably immortalized B-cells 35 (see Kabat et al., *supra*, and WO87/02671) (each of which is incorporated by reference in its entirety for all purposes). Ordinarily, the antibody will contain both light chain and

heavy chain constant regions. The heavy chain constant region usually includes CH1, hinge, CH2, CH3, and CH4 regions.

The humanized antibodies include antibodies having all types of constant regions, including IgM, IgG, IgD, IgA and

5 IgE, and any isotype, including IgG1, IgG2, IgG3 and IgG4.

When it is desired that the humanized antibody exhibit cytotoxic activity, the constant domain is usually a complement-fixing constant domain and the class is typically IgG₁. When such cytotoxic activity is not desirable, the

10 constant domain may be of the IgG₂ class. The humanized antibody may comprise sequences from more than one class or isotype.

(7) Expression Systems

15 Nucleic acids encoding humanized light and heavy chain variable regions, optionally linked to constant regions, are inserted into expression vectors. The light and heavy chains can be cloned in the same or different expression vectors. The DNA segments encoding immunoglobulin chains are operably linked
20 to control sequences in the expression vector(s) that ensure the expression of immunoglobulin polypeptides. Such control sequences include a signal sequence, a promoter, an enhancer, and a transcription termination sequence. Expression vectors are typically replicable in the host organisms either as
25 episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors will contain selection markers, e.g., tetracycline or neomycin, to permit detection of those cells transformed with the desired DNA sequences (see, e.g., U.S. Patent 4,704,362.)

30 *E. coli* is one prokaryotic host useful particularly for cloning the polynucleotides of the present invention. Other microbial hosts suitable for use include bacilli, such as *Bacillus subtilis*, and other enterobacteriaceae, such as *Salmonella*, *Serratia*, and various *Pseudomonas* species. In
35 these prokaryotic hosts, one can also make expression vectors, which will typically contain expression control sequences compatible with the host cell (e.g., an origin of replication). In addition, any number of a variety of well-known promoters

will be present, such as the lactose promoter system, a tryptophan (trp) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda. The promoters will typically control expression, optionally with an operator sequence, and have ribosome binding site sequences and the like, for initiating and completing transcription and translation.

5 Other microbes, such as yeast, may also be used for expression. *Saccharomyces* is a preferred host, with suitable vectors having expression control sequences, such as promoters, including 3-phosphoglycerate kinase or other glycolytic enzymes, and an origin of replication, termination sequences and the like as desired.

10 In addition to microorganisms, mammalian tissue cell culture may also be used to express and produce the polypeptides of the present invention (see Winnacker, *From Genes to Clones* (VCH Publishers, N.Y., N.Y., 1987)). Eukaryotic cells are actually preferred, because a number of suitable host cell lines capable of secreting intact immunoglobulins have 15 been developed in the art, and include the CHO cell lines, various Cos cell lines, HeLa cells, preferably myeloma cell lines, or transformed B-cells or hybridomas. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, and an 20 enhancer (Queen et al., *Immunol. Rev.* 89:49-68 (1986)), and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Preferred expression 25 control sequences are promoters derived from immunoglobulin genes, SV40, adenovirus, bovine papilloma virus, 30 cytomegalovirus and the like.

35 The vectors containing the polynucleotide sequences of interest (e.g., the heavy and light chain encoding sequences and expression control sequences) can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment or electroporation may be

used for other cellular hosts. (See generally Sambrook et al., *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Press, 2nd ed., 1989) (incorporated by reference in its entirety for all purposes). When heavy and light chains are cloned on separate expression vectors, the vectors are co-transfected to obtain expression and assembly of intact immunoglobulins.

Once expressed, the whole antibodies, their dimers, individual light and heavy chains, or other immunoglobulin forms of the present invention can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like (see generally Scopes, *Protein Purification* (Springer-Verlag, N.Y., 1982)). Substantially pure immunoglobulins of at least about 90 to 95% homogeneity are preferred, and 98 to 99% or more homogeneity most preferred, for pharmaceutical uses.

C. Fragments of Humanized Antibodies

In another embodiment of the invention, fragments of humanized antibodies are provided. Typically, these fragments exhibit specific binding to alph-4 integrin with an affinity of at least 10^7 M⁻¹, and more typically 10^8 or 10^9 M⁻¹. Humanized antibody fragments include separate heavy chains, light chains Fab, Fab' F(ab')₂, Fabc, and Fv. Fragments are produced by recombinant DNA techniques, or by enzymic or chemical separation of intact immunoglobulins.

II. Nucleic Acids

The humanized antibodies and fragments thereof are usually produced by expression of nucleic acids. All nucleic acids encoding a humanized antibody or a fragment thereof described in this application are expressly included in the invention.

III. Computers

In another aspect of the invention, computers programmed to display three dimensional images of antibodies on a monitor are provided. For example, a Silicon Graphics IRIS 4D

workstation running under the UNIX operating system and using the molecular modelling package QUANTA (Polygen Corp. USA) is suitable. Computers are useful for visualizing models of variants of humanized antibodies. In general, the antibodies of the invention already provide satisfactory binding affinity. However, it is likely that antibodies with even stronger binding affinity could be identified by further variation of certain amino acid residues. The three dimensional image will also identify many noncritical amino acids, which could be the subject of conservative substitutions without appreciable affecting the binding affinity of the antibody. Collectively even conservative substitutions can have a significant effect on the properties of an immunoglobulin. However, it is likely many individual conservative substitutions will not significantly impair the properties of the immunoglobulins.

IV. Testing Humanized Antibodies

The humanized antibodies of the invention are tested by a variety of assays. These include a simple binding assay for detecting the existence or strength of binding of an antibody to cells bearing VLA-4 of which one subunit is alpha-4 integrin. The antibodies are also tested for their capacity to block the interaction of cells bearing the VLA-4 receptor with endothelial cells expressing a VCAM-1 ligand. The endothelial cells may be grown and stimulated in culture or may be a component of naturally occurring brain tissue sections. See Yednock et al., *supra*, and USSN 07/871,223. The humanized antibodies are also tested for their capacity to prevent or reduce inflammation and subsequent paralysis in laboratory animals having experimental autoimmune encephalomyelitis (EAE). EAE is induced by injection of a laboratory animal with CD4⁺ T-cells specific for myelin basic protein or by directly immunizing animals with myelin basic protein. This protein is localized in the central nervous system, and the reactive T-cells initiate destruction of sheaths containing this protein in a manner that simulates the autoimmune response in multiple sclerosis. See Yednock et al., *supra*, and copending USSN 07/871,223.

V. Pharmaceutical Compositions

The invention provides pharmaceutical compositions to be used for prophylactic or therapeutic treatment comprising an active therapeutic agent, i.e., a humanized 21.6 antibody or a binding fragment thereof, and a variety of other components. The preferred form depends on the intended mode of administration and therapeutic application. The compositions can also include, depending on the formulation desired, pharmaceutically-acceptable, non-toxic carriers or diluents, which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration. The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological phosphate-buffered saline, Ringer's solutions, dextrose solution, and Hank's solution. In addition, the pharmaceutical composition or formulation may also include other carriers, adjuvants, or nontoxic, nontherapeutic, nonimmunogenic stabilizers and the like.

For parenteral administration, the antibodies of the invention can be administered as injectionable dosages of a solution or suspension of the substance in a pharmaceutically acceptable diluent with a pharmaceutical carrier which can be a sterile liquid such as water and oils with or without the addition of a surfactant and other pharmaceutically preparations are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, and mineral oil. In general, glycols such as propylene glycol or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions. The antibodies of this invention can be administered in the form of a depot injection or implant preparation which can be formulated in such a manner as to permit a sustained release of the active ingredient. A preferred composition comprises monoclonal antibody at 5 mg/mL, formulated in aqueous buffer consisting of 50 mM L-histidine, 150 mM NaCl, adjusted to pH 6.0 with HCl.

VI. Methods of Diagnosis

The humanized antibodies and their binding fragments are useful for detecting the presence of cells bearing alpha-4 integrin. The presence of such cells in the brain is 5 diagnostic of an inflammatory response and may signal the need for commencement of a therapeutic method discussed *infra*. Diagnosis can be accomplished by removing a cellular sample from a patient. The amount of expressed alpha-4 integrin in individual cells of the sample is then determined, e.g., by 10 immunohistochemical staining of fixed cells or by Western blotting of a cell extract with a humanized MAb 21.6 antibody or a binding fragment thereof.

Diagnosis can also be achieved by *in vivo* administration of a labelled humanized MAb 21.6 (or binding fragment) and 15 detection by *in vivo* imaging. The concentration of humanized MAb 21.6 administered should be sufficient that the binding to cells having the target antigen is detectable compared to the background signal. The diagnostic reagent can be labelled with a radioisotope for camera imaging, or a paramagnetic isotope 20 for magnetic resonance or electron spin resonance imaging.

A change (typically an increase) in the level of alpha-4 integrin in a cellular sample or imaged from an individual, which is outside the range of clinically established normal levels, may indicate the presence of an undesirable 25 inflammatory response reaction in the individual from whom the sample was obtained, and/or indicate a predisposition of the individual for developing (or progressing through) such a reaction. Alpha-4 integrin can also be employed as a differentiation marker to identify and type cells of certain 30 lineages and developmental origins. Such cell-type specific detection can be used for histopathological diagnosis of undesired immune responses.

VII. Methods of Treatment

The invention also provides methods of treatment that exploit the capacity of humanized MAb 21.6 to block $\alpha 4$ -dependent interactions. The $\alpha 4$ -dependent interaction with the 5 VCAM-1 ligand on endothelial cells is an early event in many inflammatory responses, including those of the central nervous system. Undesired diseases and conditions resulting from inflammation and having acute and/or chronic clinical exacerbations include multiple sclerosis (Yednock et al., 10 *Nature* 356, 63 (1992); Baron et al., *J. Exp. Med.* 177, 57 (1993)), meningitis, encephalitis, stroke, other cerebral traumas, inflammatory bowel disease including ulcerative colitis and Crohn's disease (Hamann et al., *J. Immunol.* 152, 3238 (1994)), (Podolsky et al., *J. Clin. Invest.* 92, 372 15 (1993)), rheumatoid arthritis (van Dinther-Janssen et al., *J. Immunol.* 147, 4207 (1991); van Dinther-Janssen et al., *Annals Rheumatic Diseases* 52, 672 (1993); Elices et al., *J. Clin. Invest.* 93, 405 (1994); Postigo et al., *J. Clin. Invest.* 89, 1445 (1992), asthma (Mulligan et al., *J. Immunol.* 150, 2407 20 (1993)) and acute juvenile onset diabetes (Type 1) (Yang et al., *PNAS* 90, 10494 (1993); Burkly et al., *Diabetes* 43, 529 (1994); Baron et al., *J. Clin. Invest.* 93, 1700 (1994)), AIDS dementia (Sasseville et al., *Am. J. Path.* 144, 27 (1994); atherosclerosis (Cybulsky & Gimbrone, *Science* 251, 788, Li et 25 al., *Arterioscler. Thromb.* 13, 197 (1993)), nephritis (Rabb et al., *Springer Semin. Immunopathol.* 16, 417-25 (1995)), retinitis, atopic dermatitis, psoriasis, myocardial ischemia and acute leukocyte-mediated lung injury such as occurs in adult respiratory distress syndrome.

30 Inflammatory bowel disease is a collective term for two similar diseases referred to as Crohn's disease and ulcerative colitis. Crohn's disease is an idiopathic, chronic ulceroconstrictive inflammatory disease characterized by sharply delimited and typically transmural involvement of all 35 layers of the bowel wall by granulomatous inflammatory reaction. Any segment of the gastrointestinal tract, from the mouth to the anus, may be involved, although the disease most commonly affects the terminal ileum and/or colon. Ulcerative

colitis is an inflammatory response limited largely to the colonic mucosa and submucosa. Lymphocytes and macrophages are numerous in lesions of inflammatory bowel disease and may contribute to inflammatory injury.

5 Asthma is a disease characterized by increased responsiveness of the tracheobronchial tree to various stimuli potentiating paroxysmal constriction of the bronchial airways. The stimuli cause release of various mediators of inflammation from IgE-coated mast cells including histamine, eosinophilic and neutrophilic chemotactic factors, leukotrienes, 10 prostaglandin and platelet activating factor. Release of these factors recruits basophils, eosinophils and neutrophils, which cause inflammatory injury.

Atherosclerosis is a disease of arteries (e.g., coronary, 15 carotid, aorta and iliac). The basic lesion, the atheroma, consists of a raised focal plaque within the intima, having a core of lipid and a covering fibrous cap. Atheromas compromise arterial blood flow and weaken affected arteries. Myocardial and cerebral infarcts are a major consequence of this disease. 20 Macrophages and leukocytes are recruited to atheromas and contribute to inflammatory injury.

Rheumatoid arthritis is a chronic, relapsing inflammatory disease that primarily causes impairment and destruction of joints. Rheumatoid arthritis usually first affects the small 25 joints of the hands and feet but then may involve the wrists, elbows, ankles and knees. The arthritis results from interaction of synovial cells with leukocytes that infiltrate from the circulation into the synovial lining of joints. See e.g., Paul, *Immunology* (3d ed., Raven Press, 1993).

30 Another indication for humanized antibodies against alpha-4 integrin is in treatment of organ or graft rejection. Over recent years there has been a considerable improvement in the efficiency of surgical techniques for transplanting tissues and organs such as skin, kidney, liver, heart, lung, pancreas and 35 bone marrow. Perhaps the principal outstanding problem is the lack of satisfactory agents for inducing immunotolerance in the recipient to the transplanted allograft or organ. When allogeneic cells or organs are transplanted into a host (i.e.,

the donor and donee are different individuals from the same species), the host immune system is likely to mount an immune response to foreign antigens in the transplant (host-versus-graft disease) leading to destruction of the transplanted tissue. CD8⁺ cells, CD4⁺ cells and monocytes are all involved in the rejection of transplant tissues. Antibodies directed to alpha-4 integrin are useful, *inter alia*, to block alloantigen-induced immune responses in the donee thereby preventing such cells from participating in the destruction of the transplanted tissue or organ. See, e.g., Paul et al., *Transplant International* 9, 420-425 (1996); Georczynski et al., *Immunology* 87, 573-580 (1996); Georcyznski et al., *Transplant. Immunol.* 3, 55-61 (1995); Yang et al., *Transplantation* 60, 71-76 (1995); Anderson et al., *APMIS* 102, 23-27 (1994).

A related use for antibodies to alpha-4 integrin is in modulating the immune response involved in "graft versus host" disease (GVHD). See e.g., Schlegel et al., *J. Immunol.* 155, 3856-3865 (1995). GVHD is a potentially fatal disease that occurs when immunologically competent cells are transferred to an allogeneic recipient. In this situation, the donor's immunocompetent cells may attack tissues in the recipient. Tissues of the skin, gut epithelia and liver are frequent targets and may be destroyed during the course of GVHD. The disease presents an especially severe problem when immune tissue is being transplanted, such as in bone marrow transplantation; but less severe GVHD has also been reported in other cases as well, including heart and liver transplants. The therapeutic agents of the present invention are used, *inter alia*, to block activation of the donor T-cells thereby interfering with their ability to lyse target cells in the host.

A further use of humanized antibodies of the invention is inhibiting tumor metastasis. Several tumor cells have been reported to express alpha-4 integrin and antibodies to alpha-4 integrin have been reported to block adhesion of such cells to endothelial cells. Steinback et al., *Urol. Res.* 23, 175-83 (1995); Orosz et al., *Int. J. Cancer* 60, 867-71 (1995);

Freedman et al., *Leuk. Lymphoma* 13, 47-52 (1994); Okahara et al., *Cancer Res.* 54, 3233-6 (1994).

A further use of the claimed antibodies is in treating multiple sclerosis. Multiple sclerosis is a progressive neurological autoimmune disease that affects an estimated 250,000 to 350,000 people in the United States. Multiple sclerosis is thought to be a the result of a specific autoimmune reaction in which certain leukocytes attack and initiate the destruction of myelin, the insulating sheath covering nerve fibers. In an animal model for multiple sclerosis, murine monoclonal antibodies directed against alpha-4-beta-1 integrin have been shown to block the adhesion of leukocytes to the endothelium, and thus prevent inflammation of the central nervous system and subsequent paralysis in the animals.

The humanized MAb 21.6 antibodies of the present invention offer several advantages over the mouse antibodies already shown to be effective in animals models:

1) The human immune system should not recognize the framework or constant region of the humanized antibody as foreign, and therefore the antibody response against such an injected antibody should be less than against a totally foreign mouse antibody or a partially foreign chimeric antibody.

2) Because the effector portion of the humanized antibody is human, it may interact better with other parts of the human immune system.

3) Injected mouse antibodies have been reported to have a half-life in the human circulation much shorter than the half-life of normal human antibodies (Shaw et al., *J. Immunol.* 138:4534-4538 (1987)). Injected humanized antibodies have a half-life essentially equivalent to naturally occurring human antibodies, allowing smaller and less frequent doses.

The pharmaceutical compositions discussed *supra* can be administered for prophylactic and/or therapeutic treatments of the previously listed inflammatory disorders, including multiple sclerosis, inflammatory bowel disease, asthma, atherosclerosis, rheumatoid arthritis, organ or graft rejection and graft versus host disease. In therapeutic applications,

compositions are administered to a patient suspected of, or already suffering from such a disease in an amount sufficient to cure, or at least partially arrest, the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as a therapeutically- or pharmaceutically-effective dose.

In prophylactic applications, pharmaceutical compositions are administered to a patient susceptible to, or otherwise at risk of, a particular disease in an amount sufficient to eliminate or reduce the risk or delay the outset of the disease. Such an amount is defined to be a prophylactically effective dose. In patients with multiple sclerosis in remission, risk may be assessed by NMR imaging or, in some cases, by presymptomatic indications observed by the patient.

The pharmaceutical compositions will be administered by parenteral, topical, intravenous, oral, or subcutaneous, intramuscular local administration, such as by aerosol or transdermally, for prophylactic and/or therapeutic treatment. Although the proteinaceous substances of this invention may survive passage through the gut following oral administration, subcutaneous, intravenous, intramuscular, intraperitoneal administration by depot injection; or by implant preparation. are preferred.

The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include powder, tablets, pills, capsules, and lozenges.

Effective doses of the compositions of the present invention, for the treatment of the above described conditions will vary depending upon many different factors, including means of administration, target site, physiological state of the patient, and other medicants administered. Thus, treatment dosages will need to be titrated to optimize safety and efficacy. These compositions may be administered to mammals for veterinary use and for clinical use in humans in a manner similar to other therapeutic agents, i.e., in a physiologically acceptable carrier. In general, the administration dosage will

range from about 0.0001 to 100 mg/kg, and more usually 0.01 to 5 mg/kg of the host body weight.

In a preferred treatment regime, the antibody is administered by intravenous infusion or subcutaneous injection 5 at a dose from 1 to 5 mg antibody per kilo of bodyweight. The dose is repeated at interval from 2 to 8 weeks. Within this range, the preferred treatment regimen is 3 mg antibody per kilo of bodyweight repeated at a 4 week interval.

The humanized antibodies of the invention can be used with 10 effective amounts of other therapeutic agents against acute and chronic inflammation. Such agents include antibodies and other antagonists of adhesion molecules, including other integrins, selectins, and immunoglobulin (Ig) superfamily members (see Springer, *Nature* 346, 425-433 (1990); Osborn, *Cell* 62, 3 15 (1990); Hynes, *Cell* 69, 11 (1992)). Integrins are heterodimeric transmembrane glycoproteins consisting of an α chain (120-180 kDa) and a β chain (90-110 kDa), generally having short cytoplasmic domains. For example, three important 20 integrins, LFA-1, Mac-1 and P150,95, have different alpha subunits, designated CD11a, CD11b and CD11c, and a common beta subunit designated CD18. LFA-1 ($\alpha_L\beta_2$) is expressed on lymphocytes, granulocyte and monocytes, and binds predominantly 25 to an Ig-family member counter-receptor termed ICAM-1 and related ligands. ICAM-1 is expressed on many cells, including leukocytes and endothelial cells, and is up-regulated on 30 vascular endothelium by cytokines such as TNF and IL-1. Mac-1 ($\alpha_M\beta_2$) is distributed on neutrophils and monocytes, and also binds to ICAM-1. The third β 2 integrin, P150,95 ($\alpha_X\beta_2$), is also found on neutrophils and monocytes. The selectins consist of L-selectin, E-selectin and P-selectin.

Other antiinflammatory agents that can be used in combination with the antibodies against alpha-4 integrin include antibodies and other antagonists of cytokines, such as interleukins IL-1 through IL-13, tumor necrosis factors α & β , 35 interferons α , β and γ , tumor growth factor Beta (TGF- β), colony stimulating factor (CSF) and granulocyte monocyte colony stimulating factor (GM-CSF). Other antiinflammatory agents include antibodies and other antagonists of chemokines such as

MCP-1, MIP-1 α , MIP-1 β , rantes, exotaxin and IL-8. Other antiinflammatory agents include NSAIDS, steroids and other small molecule inhibitors of inflammation. Formulations, routes of administration and effective concentrations of agents 5 for combined therapies are as described above for the humanized antibodies against alpha-4 integrin.

VIII. Other Uses

The humanized antibodies are also useful for affinity 10 purification of alpha-4 integrin. The antibodies are immobilized to a solid support and a solution of dispersed proteins is passed over the support. Alpha-4 integrin and associated β chain bind to the support and is thereby separated from other proteins. The purified alpha-4 integrin or a 15 fragment thereof, made available by this method, can be used as a vaccine or as an immunogen for producing further antibodies.

The humanized antibodies of the invention are also useful for generating idiotypic antibodies by, for example, 20 immunization of an animal with a humanized antibody. An anti-idiotype antibody whose binding to the human antibody is inhibited by alpha-4 integrin or fragments thereof is selected. Because both the anti-idiotypic antibody and the alpha-4 integrin or fragments thereof bind to the humanized 25 immunoglobulin, the anti-idiotypic antibody may represent the "internal image" of an epitope and thus may substitute a ligand of alpha-4 integrin, i.e., VCAM-1.

EXAMPLES

30 Example 1: Cloning and Sequencing of the Mouse 21.6 Variable Regions

The mouse anti-alpha-4 integrin antibody 21.6 has been described in co-pending application USSN 07/871,223. Total RNA was isolated from hybridoma cells producing mouse 21.6 antibody. First-strand cDNA was synthesized using a kit 35 (Pharmacia Biosystems Limited). Heavy and light chain variable regions were obtained by using PCR primers designed to hybridize to sequences flanking and external to the sequences

coding for the variable regions, thereby allowing cloning of the entire coding sequences for the mouse 21.6 antibody variable regions. Sense PCR primers hybridizing to the 5'-ends of mouse kappa light-chain leader sequences and of mouse heavy-chain leader sequences were designed based on databases of 42 mouse kappa light-chain leader sequences and of 55 mouse heavy-chain leader sequences (Jones & Bendig, *Bio/Technology* 9:88-89 (1991) (incorporated by reference in its entirety for all purposes)). These primers were used in conjunction with anti-sense PCR primers hybridizing to the 3'-ends of the mouse constant regions (kappa or gamma).

Mouse 21.6 kappa V_L regions were PCR-amplified in a 50 μ l reaction typically containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 200 μ M dNTPs, 1.5 mM MgCl₂, 1 unit of AmpliTaq (Perkin Elmer Cetus) DNA polymerase, 1 μ l of cDNA template, 0.25 μ M of MKV primer and 0.25 μ M of mouse kappa light chain anti-sense PCR primer (Figure 1). Mouse 21.6 V_H regions were PCR-amplified as described above except that MHVH primer and an anti-sense PCR primer specific for the mouse IgG1 heavy chain constant region were used (Figure 2). Each PCR reaction was cycled, after an initial melt at 94°C for 5 min, at 94°C for 1 min, 55°C for 1 min, and 72°C for 2 min over 25 cycles. The completion of the last cycle was followed by a final extension at 72°C for 10 min. The ramp time between the primer-annealing and extension steps was 2.5 min. Following PCR amplification, 10 μ l aliquots from each reaction were analyzed on ethidium-bromide-stained 1.5% agarose gels.

The PCR products were cloned using the "TA Cloning System" (Invitrogen Corporation). Vectors containing inserts of the correct size were sequenced using double-stranded plasmid DNA and Sequenase (United States Biochemical Corporation). To avoid any errors that might have been introduced during the PCR amplification steps, at least two independently PCR-amplified and cloned DNA fragments were sequenced for each variable region.

The sequences of PCR products were compared with other mouse light chain and heavy chain variable regions (see Tables 1 and 2). This comparison indicated that the PCR products from

MKV2 and MKV4 primers represent authentic mouse 21.6 kappa variable regions, and those from MHV1 and MHV2 primers represent authentic mouse V_H regions, and it was concluded that the sequences of these product are those of the mouse 21.6 antibody variable regions. The DNA and amino acid sequences of the cDNA coding for the mouse 21.6 V_L and V_H regions are shown in Figures 1 and 2.

Table 1

Comparison of the mouse 21.6 light chain variable region to other light chain variable regions.

<u>Mouse 21.6 V_L versus:</u>		<u>Percent Similarity</u> ¹	<u>Percent Identity</u>
15	Consensus sequence for mouse kappa V _L subgroup 5 ²	84.0	72.6
20	Consensus sequence for human kappa V _L subgroup 1 ²	84.0	69.8
25	Consensus sequence for human kappa V _L subgroup 2 ²	65.1	52.8
30	Consensus sequence for human kappa V _L subgroup 3 ²	72.6	57.5
35	Consensus sequence for human kappa V _L subgroup 4 ²	72.6	58.5
	Sequence of V _L from human REI ³ (Member of human kappa V _L subgroup 1)	81.0	72.4

¹Percent similarity was determined using the "GAP" program of the University of Wisconsin Genetics Computer Group.

40 ²Consensus sequences were taken from Kabat et al., *supra*.

³REI as sequenced by Palm et al., *Hoppe-Seyler's Z. Physiol. Chem.* 356:167-191 (1975).

Table 2

Comparison of the mouse 21.6 heavy chain variable region to other heavy chain variable regions.

5

Mouse 21.6 V_H versus:

		<u>Percent Similarity¹</u>	<u>Percent Identity</u>
10	Consensus sequence for mouse V _H subgroup 2 ^{c²}	94.3	91.1
15	Consensus sequence for human V _H subgroup 1 ²	78.0	65.0
20	Consensus sequence for human V _H subgroup 2 ²	70.5	53.3
25	Consensus sequence for human V _H subgroup 3 ²	67.5	52.8
	Sequence of V _H from human 21/28'CL ³ (Member of human V _H subgroup 1)	76.5	64.7

¹Percent similarity was determined using the "GAP" program of the University of Wisconsin Genetics Computer Group.

30 ²Consensus sequences were taken from Kabat et al., *supra*.

³21/28'CL as sequenced by Dersimonian et al., *J. Immunol.* 139:2496-2501 (1987).

35 Example 2: Construction of Chimeric 21.6 Antibody

Chimeric light and heavy chains were constructed by linking the PCR-cloned cDNAs of mouse 21.6 V_L and V_H regions to human constant regions. The 5'- and 3'-ends of the mouse cDNA sequences were modified using specially designed PCR primers. The 5'-end PCR-primers (Table 3), which hybridize to the DNA sequences coding for the beginnings of the leader sequences, were designed to create the DNA sequences essential for efficient translation (Kozak, *J. Mol. Biol.* 196:947-950 (1987)), and to create a HindIII restriction sites for cloning into an expression vector. The 3'-end primers (Table 3), which hybridize to the DNA sequences coding for the ends of J

regions, were designed to create the DNA sequences essential for splicing to the constant regions, and to create a BamHI site for cloning into an expression vector. The products of PCR amplification were digested with HindIII and BamHI, cloned 5 into a pUC19 vector, and sequenced to confirm that no errors had occurred during PCR amplification. The adapted mouse 21.6 variable regions were then subcloned into mammalian cells expression vectors containing either the human kappa or gamma-1 constant regions (Figure 3).

10

Table 3**PCR primers for the construction of chimeric 21.6 antibody.****A. Light chain variable region**

1. Primer for reconstruction of the 5'-end (37mer) (SEQ. ID NO:18)

20 5' C AGA AAG CTT GCC GCC ACC ATG AGA CCG TCT ATT CAG 3'
HindIII Kozak M R P S I Q
Consensus
Sequence

25 2. Primer for reconstruction of the 3'-end (35mer) (SEQ. ID NO:19)

30 5' CC GAG GAT CCA CTC ACG TTT GAT TTC CAG CTT GGT 3'
BamHI Splice donor site

B. Heavy chain variable region

35 1. Primer for reconstruction of the 5'-end (37mer) (SEQ. ID NO:20)

40 5' C AGA AAG CTT GCC GCC ACC ATG AAA TGC AGC TGG GTC 3'
HindIII Kozak M K C S W V
Consensus
Sequence

45 2. Primer for reconstruction of the 3'-end (33mer) (SEQ. ID NO:21)

50 5' CC GAG GAT CCA CTC ACC TGA GGA GAC GGT GAC T 3'
BamHI Splice donor site

Example 3: Expression and Analysis of 21.6 Chimeric Antibody

The two plasmid DNAs coding for the chimeric 21.6 light and heavy chains were cotransfected into Cos cells. After two or three days, media from the Cos cells was analyzed by ELISA (1) for the production of a human IgG-like antibody and (2) for 5 the ability of this human-like antibody to bind to L cells expressing human $\alpha 4\beta 1$ integrin on their surface. Figures 4 and 12 show analyses of unpurified and protein-A purified samples of chimeric 21.6 antibody for binding to human $\alpha 4\beta 1$ integrin, in comparison with purified mouse 21.6 antibody control. These 10 figures show that the chimeric 21.6 antibody bound well to antigen and confirm that the correct mouse 21.6 V_L and V_H regions had been cloned.

Example 4: Modelling the Structure of the Mouse 21.6 Variable 15 Regions

A molecular model of the V_L and V_H regions of mouse 21.6 antibody was built. The model was built on a Silicon Graphics IRIS 4D workstation running under the UNIX operating system and using the molecular modelling package QUANTA (Polygen Corp., 20 USA). The structure of the FRs of mouse 21.6 V_L region was based on the solved structure of human Bence-Jones immunoglobulin REI (Epp et al., *Biochemistry* 14:4943-4952 (1975)). The structure of the FRs of mouse 21.6 V_H region was based on the solved structure of mouse antibody Gloop2. 25 Identical residues in the FRs were retained; non-identical residues were substituted using the facilities within QUANTA. CDR1 and CDR2 of mouse 21.6 V_L region were identified as belonging to canonical structure groups 2 and 1, respectively (Chothia et al., *supra*). Since CDR1 and CDR2 of REI belong to 30 the same canonical groups, CDR1 and CDR2 of mouse 21.6, V_L region were modelled on the structures of CDR1 and CDR2 of REI. CDR3 of mouse 21.6 V_L region did not appear to correspond to any of the canonical structure groups for CDR3s of V_L regions. A database search revealed, however, that CDR3 in mouse 21.6 V_L 35 region was similar to CDR3 in mouse HyHEL-5 V_L region (Sheriff et al., *Proc. Natl. Acad. Sci. USA* 84:8075-8079 (1987)). Thus, the CDR3 of mouse 21.6 V_L region was modelled on the structure of CDR3 in mouse HyHEL-5 V_L region. CDR1 and CDR2 of mouse

21.6 V_H region were identified as belonging to canonical structure groups 1 and 2, respectively. CDR1 of mouse 21.6 V_H region was modelled on CDR1 of Gloop2 V_H region which closely resembles members of canonical group 1 for CDR1s of V_H regions.

5 CDR2 of mouse 21.6 V_H region was modelled on CDR2 of mouse HyHEL-5 (Sheriff et al., *supra*), which is also a member of canonical group 2 for CDR2 for V_H regions. For CDR3s of V_H regions, there are no canonical structures. However, CDR3 in mouse 21.6 V_H region was similar to CDR3 in mouse R19.9 V_H

10 region (Lascombe et al., *Proc. Natl. Acad. Sci. USA* 86:607-611 (1989)) and was modelled on this CDR3 by removing an extra serine residue present at the apex of the CDR3 loop of mouse R19.9 V_H region and annealing and refining the gap. The model was finally subjected to steepest descents and conjugate

15 gradients energy minimization using the CHARMM potential (Brooks et al., *J. Comp. Chem.* 4:187-217 (1983)) as implemented in QUANTA in order to relieve unfavorable atomic contacts and to optimize van der Waals and electrostatic interactions.

A view of the structural model of the mouse 21.6 variable regions is presented in Figure 5. The model was used to assist in refining the design of the humanized 21.6 antibody variable regions.

Example 5: Design of Reshaped Human 21.6 Variable Regions

25 (1) Selection of Homologous Human Antibodies for Framework Sequence

Human variable regions whose FRs showed a high percent identity to those of mouse 21.6 were identified by comparison of amino acid sequences. Tables 4 and 5 compare the mouse 21.6 variable regions to all known mouse variable regions and then to all known human variable regions. The mouse 21.6 V_L region was identified as belonging to mouse kappa V_L region subgroup 5 as defined by Kabat et al., *supra*. Individual mouse kappa V_L regions were identified that had as much as 93.4% identity to the mouse 21.6 kappa V_L region (38C13V'CL and PC613'CL). Mouse 21.6 V_L region was most similar to human kappa V_L regions of subgroup 1 as defined by Kabat et al., *supra*. Individual human kappa V_L regions were identified that had as much as 72.4%

identity to the mouse 21.6 kappa V_L region. The framework regions (FRs) from one of the most similar human variable regions, REI, were used in the design of reshaped human 21.6 V_L region. Mouse 21.6 V_H region was identified as belonging to 5 mouse V_H region subgroup 2c as defined by Kabat et al., *supra*. Individual mouse heavy chain variable regions were identified that have as much as 93.3 % identity to the mouse 21.6 V_H region (17.2.25'CL and 87.92.6'CL). Mouse 21.6 V_H region was most similar to human V_H regions of subgroup 1 as defined by 10 Kabat et al., *supra*. Individual human V_H regions were identified that had as much as 64.7% identity to the mouse 21.6 V_H region. The FRs from one of the most similar human variable regions, 21/28'CL, was used in the design of reshaped human 21.6 V_H region.

15

(2) Substitution of Amino Acids in Framework Regions
(a) Light Chain

The next step in the design process for the reshaped human 21.6 V_L region was to join the CDRs from mouse 21.6 V_L region 20 to the FRs from human REI (Palm et al., *supra*). In the first version of reshaped human 21.6 V_L region (La), seven changes were made in the human FRs (Table 4, Figure 6).

At positions 104, 105, and 107 in FR4, amino acids from REI were substituted with more typical human J region amino 25 acids from another human kappa light chain (Riechmann et al., *Nature* 332:323-327 (1988)).

At position 45 in FR2, the lysine normally present in REI was changed to an arginine as found at that position in mouse 21.6 V_L region. The amino acid residue at this position was 30 thought to be important in the supporting the CDR2 loop of the mouse 21.6 V_L region.

At position 49 in FR2, the tyrosine normally present in REI was changed to an histidine as found at that position in mouse 21.6 V_L region. The histidine at this position in mouse 35 21.6 V_L region was observed in the model to be located in the middle of the binding site and could possibly make direct contact with antigen during antibody-antigen binding.

At position 58 in FR3, the valine normally present in REI was changed to an isoleucine as found at that position in mouse 21.6 V_L region. The amino acid residue at this position was thought to be important in the supporting the CDR2 loop of the 5 mouse 21.6 V_L region.

At position 69 in FR3, the threonine normally present in REI was changed to an arginine as found at that position in mouse 21.6 V_L region. The arginine at this position in mouse 21.6 V_L region was observed in the model to be located adjacent 10 to the CDR1 loop of mouse 21.6 V_L region and could possibly make direct contact with the antigen during antibody-antigen binding.

A second version of reshaped human 21.6 V_L region (termed Lb) was designed containing the same substitutions as above 15 except that no change was made at position 49 in FR2 of REI. (Figure 6).

(b) Heavy Chain

The next step in the design process for the reshaped human 20 21.6 V_H region was to join the CDRs from mouse 21.6 V_H region to the FRs from 21/28'CL (Dersimonian et al., *J. Immunol.* 139:2496-2501 (1987)). In the first version of reshaped human 21.6 V_H region (Ha), five changes were made in the human framework regions (Table 5, Figure 7). The five changes in the 25 human FRs were at positions 27, 28, 29, 30, and 71.

At positions 27, 28, 29, and 30 in FR1, the amino acids present in human 21/28'CL were changed to the amino acids found at those positions in mouse 21.6 V_H region. Although these positions are designated as being within FR1 (Kabat et al., 30 *supra*), positions 26 to 30 are part of the structural loop that forms the CDR1 loop of the V_H region. It is likely, therefore, that the amino acids at these positions are directly involved in binding to antigen. Indeed, positions 27 to 30 are part of the canonical structure for CDR1 of the V_H region as defined by 35 Chothia et al., *supra*.

At position 71 in FR3, the arginine present in human 21/28'CL was changed to a alanine as found at that position in mouse 21.6 V_H region. Position 71 is part of the canonical

40 structure for CDR2 of the V_H region as defined by Chothia et al., supra. From the model of the mouse 21.6 variable regions, it appears that the alanine at position 71 is important in supporting the CDR2 loop of the V_H region. A substitution in 5 an arginine for an alanine at this position would very probably disrupt the placing of the CDR2 loop.

5 A second version (Hb) of reshaped human 21.6 V_H region contains the five changes described above for version Ha were 10 made plus one additional change in FR2, the arginine present in mouse 21.6 V_H region. Based on published information on the packing of V_L - V_H regions and on the model of the mouse 21.6 variable regions, it was thought that the amino acid residue at 15 position 44 might be important in the packing of the V_L - V_H regions (Chothia et al., supra) (Figure 5).

15 Reshaped human 21.6 V_H region look more similar to human VCAM-1. Both the CDR3 loop of the V_H region of antibodies is the most 20 diverse of the six CDR loops and is generally the most important single component of the antibody in antibody-antigen interactions (Chothia et al., supra; Hoogenboom & Winter, J. Mol. Biol. 227:381-388 (1992); Barbas et al., Proc. Natl. Acad. Sci. USA 89:4457-4461 (1992)). Some sequence similarity was 25 identified between the CDR3 of mouse 21.6 V_H region and amino acids 86 to 94 of human VCAM-1, particularly, between the YGN (Tyrosine-Glycine-Asparagine) sequence in the CDR3 loop and the Glycine-Aspartic acid sequence (Main et al., Cell 71:671-678 (1992)). 30 These sequences are thought to be related to the RGD (Arginine-Glycine-Aspartic acid) sequences important in various cell adhesion events (Main et al., Cell 71:671-678 (1992)).

35 Therefore, at position 98 in CDR3, the tyrosine present in mouse 21.6 V_H region was changed to a phenylalanine. Possible substitution at position 36 in FR2 was also considered. The mouse 21.6 V_H chain contains an unusual cysteine residue at position 36 in FR2. This position in FR2

is usually a tryptophan in related mouse and human sequences (Table 5). Although cysteine residues are often important for conformation of an antibody, the model of the mouse 21.6 variable regions did not indicate that this cysteine residue was involved either directly or indirectly with antigen binding so the tryptophan present in FR2 of human 21/28'CL V_H region was left unsubstituted in all three versions of humanized 21.6 antibody.

10 Example 6: Construction of Reshaped Human 21.6 Antibodies

The first version of reshaped human 21.6 V_L region (resh21.6VLa) was constructed from overlapping PCR fragments essentially as described by Daugherty et al., *Nucleic Acids Res.* 19:2471-2476 (1991). (See Figure 8). The mouse 21.6 V_L region, adapted as described in Example 2 and inserted into pUC19, was used as a template. Four pairs of primers, APCR1-vla1, vla2-vla3, vla4-vla5, and vla6-vla7 were synthesized (Table 6 and Figure 8). Adjacent pairs overlapped by at least 21 bases. The APCR1 primer is complementary to the pUC19 vector. The appropriate primer pairs (0.2 μ moles) were combined with 10 ng of template DNA, and 1 unit of AmpliTaq DNA polymerase (Perkin Elmer Cetus) in 50 μ l of PCR buffer containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 200 μ M dNTPs, and 1.5 mM MgCl₂. Each reaction was carried out for 25 cycles. After an initial melt at 94° for 5 min, the reactions were cycled at 94°C for 1 min, 55°C for 1 min, and 72°C for 2 min, and finally incubated at 72°C for a further 10 min. The ramp time between the primer-annealing and extension steps was 2.5 min. The products of the four reactions (A, B, C, and D) from the first round of PCR reactions were phenol-extracted and ethanol-precipitated.

Table 6
PCR primers for the construction of reshaped
human 21.6 variable regions.

5

A. Light chain variable region

1. Primers for the synthesis of version "a"

10 21.6VLa1 (39mer) (SEQ. ID NO:22):
 5' GAT GGT GAC TCT ATC TCC TAC AGA TGC AGA CAG TGA GGA 3'
 15 21.6VLa2 (32mer) (SEQ. ID NO:23):
 5' CTG TAG GAG ATA GAG TCA CCA TCA CTT GCA AG 3'
 20 21.6VLa3 (39mer) (SEQ. ID NO:24):
 5' AGG AGC TTT TCC AGG TGT CTG TTG GTA CCA AGC CAT ATA 3'
 25 21.6VLa4 (41mer) (SEQ. ID NO:25):
 5' ACC AAC AGA CAC CTG GAA AAG CTC CTA GCC TGC TCA TAC AT 3'
 30 21.6VLa5 (40mer) (SEQ. ID NO:26):
 5' GCA GGC TGC TGA TGG TGA AAG TAT AAT CTC TCC CAG ACC C 3'
 35 21.6VLa6 (42mer) (SEQ. ID NO:27):
 5' ACT TTC ACC ATC AGC AGC CTG CAG CCT GAA GAT ATT GCA ACT 3'
 40 21.6VLa7 (59mer) (SEQ. ID NO:28):
 5' CCG AGG ATC CAC TCA CGT TTG ATT TCC ACC TTG GTG CCT TGA CCG AAC GTC
 3' CAC AGA TT 3'

2. Primers for the synthesis of version "b"

35 21.6VLb1 (33mer) (SEQ. ID NO:29): changes H-49 to Y-49
 5' GGA AAA GCT CCT AGG CTG CTC ATA TAT TAC ACA 3'
 40 21.6VLb2 (38mer (SEQ. ID NO:30)): changes ACC-101 to ACA-101 to
 destroy an StyI site
 5' CCG AGG ATC CAC TCA CGT TTG ATT TCC ACC TTT GTG CC 3'

B. Heavy chain variable region

1. Primers for the synthesis of version "a"

45 21.6VHa1 (51mer) (SEQ. ID NO:31):
 5' AAC CCA GTG TAT ATA GGT GTC TTT AAT GTT GAA ACC GCT AGC TTT ACA GCT
 3'
 50 21.6VHa2 (67mer) (SEQ. ID NO:32):
 5' AAA GAC ACC TAT ATA CAC TGG GTT AGA CAG GCC CCT GGC CAA AGG CTG GAG
 TGG ATG GGA AGG ATT G 3'
 55 21.6VHa3 (26mer) (SEQ. ID NO:33):
 5' GAC CCG GCC CTG GAA CTT CGG GTC AT 3'
 60 21.6VHa4 (66mer) (SEQ. ID NO:34):
 5' GAC CCG AAG TTC CAG GGC CGG GTC ACC ATC ACC GCA GAC ACC TCT GCC AGC
 ACC GCC TAC ATG GAA 3'
 65 21.6VHa5 (64mer) (SEQ. ID NO:35):
 5' CCA TAG CAT AGA CCC CGT AGT TAC CAT AAT ATC CCT CTC TGG CGC AGT AGT
 AGA CTG CAG TGT C 3'

21.6VHa6 (63mer) (SEQ. ID NO:36):
5' GGT AAC TAC GGG GTC TAT GCT ATG GAC TAC TGG GGT CAA GGA ACC CTT GTC
ACC GTC TCC TCA 3'

5

2. Primer for the synthesis of version "b"

21.6VHb (37mer) (SEQ. ID NO:37): changes R-44 to G-44
5' CCA GGG CCG GGT CAC CAT CAC CAG AGA CAC CTC TGC C 3'

10

3. Primer for the synthesis of version "c"

21.6VHc (27mer) (SEQ. ID NO:38): changes Y-98 to F-98
5' CAG GCC CCT GCC CAA GGG CTG GAG TGG 3'

C. Both light and heavy chain variable regions

20 Primers hybridizing to the flanking pUC19 vector DNA

APCR1 (17mer (SEQ. ID NO:39), sense primer)
5' TAC GCA AAC CGC CTC TC 3'

25 APCR4 (18mer (SEQ. ID NO:40), anti-sense primer)
5' GAG TGC ACC ATA TGC GGT 3'

PCR products A and B, and C and D were joined in a second
30 round of PCR reactions. PCR products A and B, and C and D, (50
ng of each) were added to 50 μ l PCR reactions (as described
above) and amplified through 20 cycles as described above,
except that the annealing temperature was raised to 60°C. The
products of these reactions were termed E and F. The pairs of
35 PCR primers used were APCR1-vla3 and vla4-vla7, respectively.
PCR products E and F were phenol-extracted and ethanol-
precipitated and then assembled in a third round of PCR
reactions by their own complementarity in a two step-PCR
reaction similar to that described above using APCR1 and vla7
40 as the terminal primers. The fully assembled fragment
representing the entire reshaped human 21.6 V_L region including
a leader sequence was digested with HindIII and BamHI and
cloned into pUC19 for sequencing. A clone having the correct
sequence was designated resh21.6VLa.

45 The second version of a reshaped human 21.6 V_L region (Lb)
was constructed using PCR primers to make minor modifications
in the first version of reshaped human 21.6 V_L region (La) by
the method of Kamman et al., *Nucl. Acids Res.* 17:5404 (1989).

Two sets of primers were synthesized (Table 6). Each PCR reaction was essentially carried out under the same conditions as described above. In a first PCR reaction, mutagenic primer 21.6VLb2 was used to destroy a StyI site (Thr-ACC-97 to Thr-5 ACA-97) to yield resh21.6VLa2. Then, in a second PCR reaction, mutagenic primer 21.6VLb1 (His-49 to Tyr-49) was used with pUC-resh21.6VLa2 as template DNA. The PCR product was cut with StyI and BamHI and subcloned into pUC-resh21.6VLa2, cleaved with the same restriction enzymes. A clone with the correct 10 sequence was designated pUC-resh21.6VLb.

Version "a" of a reshaped human 21.6 V_H region was constructed using the same PCR methods as described for the construction of version "a" of reshaped human 21.6 V_L region (Table 6 and Figure 9). The HindIII-BamHI DNA fragments coding 15 for version "g" of reshaped human 425 V_H region (Kettleborough et al., *supra*) and version "b" of reshaped human AUK12-20 V_H region were subcloned into pUC19 vectors yielding pUC-resh425g and pUC-reshAUK12-20b, respectively. (Version "b" of AUK12-20, was derived by PCR mutagenesis of a fragment $V_{H4}425$ described 20 by Kettleborough et al., *supra*, and encodes the amino acid sequence (SEQ. ID NO:41):

QVQLVQSGAEVKPGASVKVSCKASGYSFT SYYIH WVRQAPGQGLEWVG
25 YIDPFNNGGTSYNQKFKG KVTMTVDTSTNTAYMELSSLRSEDTAVYYCAR GGN-RFAY WGQGTLVTVSS
(spaces separate FR and CDR regions)).

30 Plasmid pUC-resh425g and pUC-reshAUK12-20b, as well as the pUC vector containing the mouse 21.6 V_H region as modified for use in the construction of the chimeric 21.6 heavy chain (pUC-chim21.6VH), were used as template DNAs in the subsequent PCR reactions. PCR primers were designed and synthesized for the 35 construction of version "a" of reshaped human 21.6 V_H region (Table 6). PCR product A (Figure 9) was obtained using pUC-reshAUK12-20b as DNA template and APCR1-vha1 as the PCR primer pair. PCR products B and D were obtained using pUC-chim21.6VH as DNA template and vha2-vha3 and vha6-APCR4 as PCR primer 40 pairs, respectively. Finally, PCR product C was obtained using pUC-resh425g as DNA template and vla4-vla5 as the PCR primer pair. The final PCR product was subcloned into pUC19 as an

HindIII-BamHI fragment for DNA sequencing. A clone with the correct DNA sequence was designated pUC-resh21.6VHa. The DNA and amino acid sequences of the first version of the reshaped 21.6 variable region are shown in Figure 10.

5 The remaining versions of reshaped human 21.6 V_H region were constructed essentially as described above for the construction of version "b" of reshaped human 21.6 V_L region. Two sets of primers were synthesized (Table 6). For the second (Hb) and third (Hc) versions, mutagenic primers 21.6VHb (Arg-44 10 to Gly-44) and 21.6VHc (Tyr-98 to Phe-98), respectively, were used in PCR reactions with pUC-resh21.6VHa as the template DNA. The PCR products VHb and VHc were cut with restriction enzymes and subcloned into pUC vector pUC-resh21.6VHa as MscI-BamHI and PstI-BamHI fragments, respectively, to yield pUC-resh21.6VHb 15 and pUC-resh21.6VHc.

The first version of a reshaped human 21.6 V_H region (Ha) was constructed in a similar manner to that used for the construction of the first version of reshaped human 21.6 V_L region (La). In this case, however, PCR primers were used with 20 three different template DNAs, mouse 21.6 V_H region as already adapted for expression of chimeric 21.6 heavy chain, humanized 425 V_H region version "g" (Kettleborough et al., *supra*), and humanized AUK12-20 version "b" V_H region (Table 6, Figure 9). The DNA and amino acid sequences of the first version of the 25 humanized 21.6 heavy chain variable region are shown in Figure 11. The second and third versions of a humanized 21.6 V_H region (Hb and Hc) were constructed using PCR primers to make minor modifications in the first version of humanized 21.6 V_H region (Ha) (Table 6).

30

Example 7: Expression and Analysis of Humanized Antibodies

1. Linkage of Variable Regions to Constant Regions in Expression Vectors

The DNA fragments coding for the chimeric and reshaped 35 21.6 V_L and V_H regions were subcloned into HCMV vectors designed to express either human kappa light chains or human gamma-1 heavy chains in mammalian cells (see Figure 3) and Maeda et al., *Hum. Antibod. Hybridomas* 2:124-134 (1991). Both

vectors contain the human cytomegalovirus (HCMV) promoter and enhancer for high level transcription of the immunoglobulin light and heavy chains. The light chain expression vector is exactly as described in Maeda et al., *supra*, and contains 5 genomic DNA coding for the human kappa constant region (Rabbitts et al., *Curr. Top. Microbiol. Immunol.* 113:166-171 (1984)). The heavy chain expression vector is essentially as described in Maeda et al., *supra*, with the exception that the 10 genomic DNA coding for the human gamma-1 constant region was replaced with a cDNA. cDNA coding for human gamma-1 constant 15 region was cloned from a human cell line that secreted a human gamma-1 antibody by PCR. For convenient subcloning into the expression vector, BamHI sites were created at each end of the cDNA. In addition, a splice acceptor site and a 65 bp intron 20 sequence were created at the 5'-end of the cDNA sequence. The BamHI fragment (1176 bp) containing the human gamma-1 cDNA splice acceptor site and intron sequence was substituted for the BamHI fragment (approximately 2.0 kb) in the existing heavy chain vector (Maeda et al., *supra*). The BamHI site to the 3'- side of the human gamma-1 constant region was then removed with Klenow polymerase.

2. Transfection of Expression Vectors

Expression vectors were introduced into Cos cells by 25 electroporation using the Gene Pulsar apparatus (BioRad). DNA (10 μ g of each vector) was added to a 0.8 ml aliquot of 1×10^7 cells/ml in PBS. A pulse was delivered at 1,900 volts, 25 μ F capacitance. After a 10 min recovery period at ambient 30 temperature, the electroporated cells were added to 8 ml of DMEM (GIBCO) containing 5% heat-inactivated gamma globulin-free fetal calf serum. After 72 h incubation, the medium was collected, centrifuged to remove cellular debris, and stored under sterile conditions at 4°C for short periods of time, or at -20°C for longer periods.

3. Purification of Humanized Antibodies

Supernatants from Cos cell transfections were pooled and purified on immobilized Protein A (ImmunoPure IgG Purification Kit, Pierce). The supernatant was sterilized by filtration through a 0.22 μ m filter. After mixing with an equal volume of ImmunoPure IgG binding buffer (pH 8.0), the diluted sample was applied to a 1 ml protein A column and allowed to flow completely into the gel. After washing with 15 ml of ImmunoPure IgG binding buffer, the bound antibody was eluted with 5 ml of ImmunoPure IgG elution buffer (pH 2.8), and 1 ml fractions were collected. The pH of the first and second fractions was approximately 8.0. The pH of the third fraction was adjusted to physiological pH by the addition of 100 μ l of ImmunoPure binding buffer. The five 1 ml fractions containing the Protein A-purified antibody were then assayed by ELISA to determine the amount of human IgG antibody present in each fraction. Antibody was detected using goat alkaline phosphate-conjugated anti-human IgG (whole molecule, Sigma).

4. Measurement of Binding Affinity

The binding of reshaped human 21.6 antibodies to $\alpha 4\beta 1$ integrin was assayed by ELISA in comparison with mouse and chimeric antibodies. Briefly, L cells transformed to express $\alpha 4\beta 1$ integrin on their cell surface were plated out and grown to confluence in 96-well tissue culture plates. The samples to be tested (either crude supernatants or protein-A-purified) were serially diluted and added to each well. After incubation for 1 h on ice and very gentle washing, goat anti-mouse or anti-human (gamma-chain specific) peroxidase conjugates (Sigma) were added. After a further 1 h incubation on ice and very gentle washing, the substrate (o-phenylenediamine dihydrochloride, Sigma) was added. After incubation for 30 min at room temperature, the reaction was stopped by adding 1 M H_2SO_4 , and the A_{490} was measured.

Results from analyzing crude supernatants of the two versions of reshaped human 21.6 light chains (La and Lb), in combination with version Ha of reshaped human 21.6 heavy chain, indicated that the La version of reshaped human 21.6 V_L region

gave slightly better binding to antigen than version Lb. The La version was therefore used in subsequent experiments. Results from analysis of the crude supernatants of humanized 21.6 heavy chains (Ha and Hb), in combination with version La of humanized 21.6 light chain, showed no significant difference between the two versions (Ha and Hb) of reshaped human V_H regions. Version Ha was selected for use in further experiments because it contained only five changes in the human FRs compared with six changes in the human Hb.

Figure 12 compares binding of humanized 21.6 antibody (La + Ha) with chimeric 21.6 antibody. The data indicate that the reshaped human 21.6 antibody (La + Ha) bound to antigen as well as, and perhaps slightly better than, the chimeric 21.6 antibody. The chimeric 21.6 antibody is expected to be equivalent to mouse 21.6 antibody in its antigen binding characteristics because it contains the intact mouse 21.6 variable regions. The reshaped human 21.6 antibody (La + Ha) has also been shown to block binding to human $\alpha 4\beta 1$ integrin with an efficiency comparable to the original mouse 21.6 antibody and to the chimeric antibody. It is therefore concluded that reshaped human 21.6 antibody (La + Ha) has a specific binding affinity essentially equal to that of mouse 21.6 antibody. Moreover, because only minor modifications in the human FRs were necessary to recreate the antigen binding site of mouse 21.6 antibody within human variable regions, the reshaped human 21.6 antibody is predicted to behave like an authentic human antibody.

Reshaped human 21.6 antibody containing version La of the reshaped human 21.6 VL region and version Hc of the reshaped human 21.6 VH region was also tested for binding to L cells expressing human $\alpha 4\beta 1$ integrin on their surface in parallel with chimeric 21.6 antibody. The results indicate that reshaped human 21.6 antibody (La + Hc) binds well to antigen. The alteration in the CDR3 of the V_H region did not impair binding to antigen. Indeed, there is some indication that the alteration in the CDR3 may have slightly improved binding to antigen (Figure 12). Conceivably, the improvement may be more pronounced in a functional blocking assay.

Example 8: Blocking Properties of Mu 21.6 Antibody

Mu 21.6 was compared with another antibody against α_4 integrin called L25. L25 is commercially available from Becton Dickinson, and has been reported in the literature to be a good inhibitor of $\alpha_4\beta_1$ integrin adhesive function. As shown in Figure 13 (Panel A), both Mu 21.6 and L25 completely inhibited $\alpha_4\beta_1$ integrin-dependent adhesion of human monocytic cells to purified VCAM-1 in the absence of Mn^{+2} . However, in the presence of Mn^{+2} (1 mM) (one of several activators of $\alpha_4\beta_1$ integrin) L25 was no longer an effective inhibitor. Similar results were observed when $\alpha_4\beta_1$ integrin was activated by other stimuli. The capacity to block activated $\alpha_4\beta_1$ integrin is likely to be of value in treating inflammatory diseases such as multiple sclerosis.

As a further comparison between mu 21.6 and L25, the capacity of antibody to inhibit human T cell adhesion to increasing amounts of VCAM-1 was determined. In this experiment, increasing amounts of VCAM-1 were coated onto plastic wells of a 96 well assay plate, and the ability of the human T cell line, Jurkat (which expresses high levels of $\alpha_4\beta_1$ integrin), to bind to the coated wells was measured. Values on the Y-axis represent the percentage of Jurkat cells originally added to each well that remained bound after washing the well four times (Figure 13 (Panel B)). This experiment demonstrates that L25 is a good inhibitor of cell adhesion when low levels of VCAM-1 are encountered, but becomes completely ineffective at higher levels of VCAM-1. Mu 21.6, on the other hand, inhibits cell adhesion completely, regardless of the amount of VCAM-1 present. The capacity to block at high concentrations of VCAM-1 is desirable for therapeutic applications because of upregulation of VCAM-1 at sites of inflammation.

Example 9: Efficacy of Humanized 21.6 Antibody in An Animal Model

This example establishes the efficacy of humanized 21.6 antibody in prophylactic and therapeutic treatment of EAE in an animal model simulating multiple sclerosis in humans.

(a) Methods(1) Induction of EAE

The brain and spinal cord were removed from each of five guinea pigs euthanized by CO₂ narcosis. The tissue was kept in 5 PBS on wet ice until it was weighed and homogenized at a concentration of 1 gram of tissue per ml PBS. The tissue was completely homogenized using an electric hand-held homogenizer and subsequently mixed with an equal volume of Freund's complete adjuvant (FCA). FCA was made by adding 100 mg of 10 *mycobacterium tuberculosis* H37 RA (DIFCO, 3114-33-8) to 10 ml of Freund's incomplete adjuvant (Sigma, F-5506). The mixture was emulsified into the consistency of mayonnaise by passing the solution between two syringes connected by a two way stopcock. Each guinea pig was immunized with 600 μ l emulsion 15 divided between three sites of administration.

(2) Scoring animals for disease symptoms

The disease symptoms were assessed by prompting each animal to walk and assigning the animal a score by the 20 following commonly accepted criteria:

- 0 No disease
- 1 Hind limb weakness
- 2 Complete hind limb paralysis
- 3 Complete hind limb and some forelimb paralysis
- 25 4 Moribund or dead

(3) Serum and tissue collection

Samples were collected by cardiac puncture from 30 methoxyflurane-anesthetized guinea pigs. About 300-400 μ l of blood were collected and placed in microtainer serum separator and allowed to clot for between 20-30 min at room temperature. The tube was then spun for 5 min at room temperature. The serum was drawn off into Eppendorf tubes and stored at -20°C 35 for subsequent analysis of antibody titers by fluorescence activated cell sorting (FACS).

For hematological analysis, blood was collected into ethylenediaminetetraacetic acid-coated microtainer tubes. A 40 100 μ l aliquot was aspirated into an acridine-coated hematocrit tube. The tube was capped and the blood was mixed with acridine orange by gently inverting the tube 15 times. A float

was put into the hematocrit tube and the sample was centrifuged for 5 minutes. The hematocrit tube was placed into a precalibrated Idexx QBC Vet Autoreader designed for quantitative buffey coat analysis. Values were read under the 5 horse calibration system and adjusted to guinea pig equivalents using a predetermined conversion factor.

At the end of the experiment, the guinea pigs were killed by CO₂ narcosis and the brains and spinal cords removed. Half of the brain and spinal cord from every guinea pig was snap 10 frozen in 2-methyl butane on dry ice (-20 to -40°C). This tissue was cut and immunostained with a pan macrophage marker (Serotec MCA-518) and a T-lymphocyte marker (Serotec MCA-751) using the avidin-biotin linking peroxidase assay (Vector 15 Laboratories, Inc., Burlingame, CA) and diaminobenzidine as a chromagen. The tissue was scored for cellular infiltration according to the following scoring system:

- 0 No infiltrating cells.
- 20 0.5 Very little staining; may be artifactual; usually associated with vessels.
- 25 1 Staining of a few cells (less than 15) usually near a vessel.
- 30 2 Staining of many cells (20-50), usually radiating out from a vessel.
- 35 3 Staining of many cells (> 50) scattered throughout the tissue; many cuffed vessels.

(b) Prophylactic Treatment

This experiment was designed to evaluate the efficacy of humanized 21.6 antibody in delaying the onset of clinical 35 symptoms. Previous data have demonstrated that leukocyte influx into the brain and spinal cord of EAE guinea pigs typically starts between day 7 and day 8. Therefore, antibodies were administered on day 7 and on day 10 post-immunization. To compare mouse and humanized 21.6 antibody, 40 equivalent doses of each of the antibodies (3.0, 0.30 and 0.03 mg/kg) were administered. Preliminary pharmacokinetic studies revealed that saturating blood levels of mouse 21.6

antibody were attained within 24 hours after subcutaneous administration, and remained elevated up to 48 hours.

On day 11, 24 hours after the second dose of antibody, blood samples were drawn from three randomly selected animals in each group. For each treatment group a mean for the number of days for each guinea pig to reach a clinical score of 1 was calculated (Table 7). The mean value for the PBS-treated group in this experiment was 11 days post-immunization (which is typical of previous results). Treatment with the highest dose of humanized and mouse antibody resulted in a significant delay of disease by 4.6 ($p=0.000$) and 3 ($p=0.007$) days, respectively. The lower doses of antibody had no effect on the course of disease.

15

Table 7

Effect of mouse or humanized 21.6 antibody on time post immunization to reach a clinical score of 1.

GROUP	1	2	3	4	5	6	7
mg/kg	0.03 M [#]	3.0 H [@]	3.0 H	3.0 M	0.03 H	PBS	0.3 M
	8	9	13	10	8	9	9
	9	10	15	12	10	9	9
	9	10	15	14	10	11	11
	9	11	16	14	11	11	12
	11	11	16	14	12	11	12
	12	11	16	15	12	12	13
	12	12	17	15	12	12	13
		13	17	18	12	13	
Mean ± SD	10.0 ± 1.6	10.9 ± 1.2	**15.6 ± 1.3	*14.0 ± 2.3	10.9 ± 1.5	11.0 ± 1.4	11.6 ± 1.4

[@] H denotes humanized antibody; [#] M denotes mouse.

** $p=0.000$ and * $p=0.007$, as compared to PBS.

30

Daily body weights of the guinea pig reflected a similar effect of the high doses of humanized and mouse antibody. (Figure 14). Animals in these treatment groups steadily gained weight. Guinea pigs in all other treatment groups lost weight starting from just before the day of onset of disease.

35

Serum titers of antibody were measured in three randomly selected animals from each group by cardiac puncture on day 11, roughly 24 hr after the second treatment. Efficacy of the antibodies to delay disease correlated tightly with serum 5 levels. About 20 μ g/ml serum antibody was present in the circulation of all animals injected with the highest dose of both humanized and mouse antibodies. This concentration is of the same order of magnitude as the concentration of 21.6 antibody required to saturate alph-4 integrin sites *in vitro*. 10 In contrast, animals from all other groups had little to no detectable serum antibody.

(c) Reversal of On-going Disease

About 60 guinea pigs were immunized and allowed to 15 develop clinical symptoms of EAE. On day 13, all guinea pigs that attained a clinical score of 1 were randomly assigned to a treatment group. Figure 15 shows that animals treated with 3 mg/kg humanized antibody began to recover hind limb function within 48 hr of treatment. On Days 17 and 18, one and two 20 days after the second dose, all eight animals were disease free. ANOVA of the area under the curve values for each treatment group revealed that only the 3 mg/kg humanized antibody treated group value was statistically lower than the PBS control group ($p=0.042$). These animals progressively 25 gained weight within 24 hrs after the first administration until the experiment was terminated on Day 19 (Figure 16).

Antibody serum titers were measured by FACS analysis on samples taken 24 hrs after the first injection (Day 14) and at sacrifice (Day 19). Treatment with mouse 21.6 antibody 30 resulted in slightly lower serum antibody titers than treatment with humanized 21.6 antibody (9.1 vs. 12.6 μ g/ml). This difference became more profound on Day 19, three days after the second administration, when there was very little detectable serum mouse antibody, while the levels of humanized 35 antibody on Day 19 had dropped below saturating but were still measurable (6.1 μ g/ml). These data demonstrate a correlation between plasma levels of antibody and physiologic efficacy and

suggest that the effective circulating antibody level is in the range of 10-20 μ g/ml in the guinea pig.

Leukocyte infiltration onto brain and spinal cord was evaluated in tissue from animals killed on Day 19. Table 8 shows significant differences in the degree of infiltration as a function of antibody treatment. The reduction in T cell infiltration into brain and spinal cord and macrophage infiltration into spinal cord was significant after treatment with 3 mg/kg. Lower doses tended to reduce infiltration, but did not reach significance. There was no significant difference in cellular infiltrate of macrophages into the spinal cord at any dose. Since the immunohistochemical technique used to evaluate macrophages does not distinguish resident from invading cells, the lack of effect on macrophages likely represents the sustained presence of resident macrophages and microglia.

The reduction in T-cells and monocytes in brain tissue by administration of the antibody after establishment of the disease suggests that cell trafficking is not a cumulative process, but a dynamic movement of cells into and out of CNS tissue. Importantly, the data suggest that interruption of the entry of leukocytes into parenchymal tissue allows the CNS to rid itself of the invading pathological element.

25

Table 8

Significant differences in T-cell and macrophage infiltration into brain and spinal cord on Day 129.

30

BRAIN

SPINAL CORD

GROUP PBS	T-CELLS	MACROPHAGES	T-CELLS	MACROPHAGES
3 mg/kg @ H	p=0.001	p=0.005	p=0.007	NS
3 mg/kg # M	p=0.001	p=0.005	p=0.008	NS
1mg/kg H	NS	NS	NS	NS
0.3 mg/kg H	NS	NS	NS	NS

NS = not significant.

40

Hematology data revealed that treatment with mouse or humanized 21.6 antibody caused no difference in whole white blood cell counts, mononuclear and granulocyte number or in red blood cell count. The high dose of mouse or humanized antibody resulted in a significant increase in platelet counts as compared to PBS treated animals (Table 9). In normal guinea pig platelet counts are 755 ± 103 cells/ml, about double that of PBS-treated EAE animals. Thus, treatment with doses of mouse and humanized antibody that effectively reversed disease, also restored platelet count to normal.

Table 9

Effect of antibody treatment on platelet count in EAE animals.

15

TREATMENT	PLATELETS $\times 10^{-6}$ CELLS/ML
++Non EAE guinea pigs	755 ± 103 (9)
PBS	373.7 ± 167.5 (7)
3 mg/kg θ H	622.2 ± 97.0 (6) **
20 3 mg/kg $\#$ M	587.5 ± 57.8 (6)
1 mg/kg H	578.3 ± 123.2 (6)
0.3 mg/kg H	492.5 ± 168.6 (6)

25 ** Platelet counts in non-EAE guinea pigs were determined in a separate experiment.

*p=0.05 vs PBS.

30 In conclusion, both humanized and mouse 21.6 antibodies are effective in delaying and reversing clinical symptoms in an animal model simulating multiple sclerosis in humans. The humanized antibody is more effective than the same dosage of mouse antibody in reversing symptoms.

35 Although the foregoing invention has been described in detail for purposes of clarity of understanding, it will be obvious that certain modifications may be practiced within the scope of the appended claims. All publications and patent documents cited above are hereby incorporated by reference in

their entirety for all purposes to the same extent as if each were so individually denoted.

Table 4
Alignment of amino acid sequences leading to the design
of reshaped human 21.6 light chain variable regions.

	Kabat	#	FR or CDR	mouse 21.6	mouse kappa 5 (SEQ. ID NO:42)	human kappa 1 (SEQ. ID NO:43)	human REI	RH V _L 21.6	Comment
5	1	1	FR1	D	D	D	D	D	
10	2	2		I	I	I	I	I*	
15	3	3		Q	Q	Q	Q	Q	
20	4	4		M	M	M	M	M	
25	5	5		T	T	T	T	T	
30	6	6		Q	Q	Q	Q	Q	
35	7	7		S	S	S	S	S	
	8	8		P	P	P	P	P	
	9	9		S	S	S	S	S	
	10	10		S	S	S	S	S	
	11	11		L	L	L	L	L	
	12	12		S	S	S	S	S	
	13	13		A	A	A	A	A	
	14	14		S	S	S	S	S	
	15	15		L	L	V	V	V	
	16	16		G	G	G	G	G	
	17	17		G	D	D	D	D	
	18	18		K	R	R	R	R	
	19	19		V	V	V	V	V	
	20	20		T	T	T	T	T	
	21	21		I	I	I	I	I	
	22	22		T	T	T	T	T	
	23	23	FR1	C	C	C	C	C	
	24	24	CDR1	K	R	R	Q	K	
	25	25		T	A	A	A	T*	
	26	26		S	S	S	S	S*	
	27	27		Q	Q	Q	Q	Q*	
	27A			-	D	S	-	-	
	27B			-	-	L	-	-	
	27C			-	-	V	-	-	

		27D			-	-	X	-	-	
		27E			-	-	X	-	-	
		27F			-	-	-	-	-	
5	28	28	{	D	D	S	D	D*		
	29	29		I	I	I	I	I*		
	30	30		N	S	S	I	N*		
	31	31		K	N	N	K	K*		
10	32	32		Y	Y	Y	Y	Y*		
	33	33		M	L	L	L	M*		
	34	34	CDR1	A	N	A	N	A		
	35	35	FR2	W	W	W	W	W		
	36	36		Y	Y	Y	Y	Y		
	37	37		Q	Q	Q	Q	Q		
15	38	38		H	Q	Q	Q	Q		
	39	39		K	K	K	T	T	K in CAMPATH- 1H	
	40	40		P	P	P	P	P		
	41	41		G	G	G	G	G		
	42	42		K	G	K	K	K		
20	43	43		R	S	A	A	A	consider R in other versions	
	44	44		P	P	P	P	P		
	45	45		R	K	K	K	R	supports L2 loop, consider K in other versions	
	46	46		L	L	L	L	L		
	47	47		L	L	L	L	L		
	48	48		I	I	I	I	I*		
25	49	49	FR2	H	Y	Y	Y	H	in middle of binding site, potential to interact with antigen, consider Y in other versions	
	50	50	CDR2	Y	Y	A	E	Y*		
	51	51		T	A	A	A	T*		
	52	52		S	S	S	S	S*		

			A	R	S	N	A	
5	53	53	I	L	L	L	L	
	54	54	I	Q	H	E	Q	Q
	55	55	CDR2	P	S	S	A	P
	56	56	FR3	G	G	G	G	G
	57	57						
	58	58	I	I	V	V	V	I
	59	59	I	P	P	P	P	
10	60	60	I	S	S	S	S	
	61	61	I	R	R	R	R	R
	62	62	I	F	F	F	F	F
	63	63	I	S	S	S	S	S
	64	64	I	G	G	G	G	G*
	65	65	I	S	S	S	S	S
	66	66	I	G	G	G	G	G
15	67	67	I	S	S	S	S	S
	68	68	I	G	G	G	G	G
	69	69	I	R	T	T	T	R
	70	70	I	D	D	D	D	D
20	71	71	I	Y	Y	F	Y	Y*
	72	72	I	S	S	T	T	T
	73	73	I	F	L	L	F	F
	74	74	I	N	T	T	T	T
	75	75	I	I	I	I	I	I
	76	76	I	S	S	S	S	S
25	77	77	I	N	N	S	S	S
	78	78	I	L	L	L	L	L
	79	79	I	E	E	Q	Q	Q
	80	80	I	P	Q	P	P	P
	81	81	I	E	E	E	E	E
30	82	82	I	D	D	D	D	D
	83	83	I	I	I	F	I	I

	84	84	I	A	A	A	A	
5	85	85	I	T	T	T	T	
	86	86	I	Y	Y	Y	Y	
	87	87	I	Y	F	Y	Y	
	88	88	FR3	C	C	C	C	
10	89	89	CDR3	L	Q	Q	Q	L
	90	90	I	Q	Q	Q	Q	Q*
	91	91	I	Y	G	Y	Y	Y*
	92	92	I	D	N	N	Q	D*
15	93	93	I	N	T	S	S	N*
	94	94	I	L	L	L	L	L*
	95		I	-	P	P	P	-
	95A		I	-	P	E	-	-
	95B		I	-	-	-	-	-
20	95C		I	-	-	-	-	-
	95D		I	-	-	-	-	-
	95E		I	-	-	-	-	-
	95F		I	-	-	-	-	-
	96	95	I	W	R	W	Y	W*
25	97	96	CDR3	T	T	T	T	T
	98	97	FR4	F	F	F	F	F
	99	98	I	G	G	G	G	G
	100	99	I	G	G	Q	Q	Q
	101	100	I	G	G	G	G	G
30	102	101	I	T	T	T	T	T
	103	102	I	K	K	K	K	K
	104	103	I	L	L	V	L	V
	105	104	I	E	E	E	Q	E
	106	105	I	I	I	I	I	I
	106A		I	-	-	-	-	-
	107	106	FR4	K	K	K	T	K

Legend: (Kabat) numbering according to Kabat et al., *supra*; (#) sequential numbering as used in the molecular modelling; (mouse 21.6) amino acid sequence of the V_L region

from mouse 21.6 antibody; (mouse kappa 5) consensus sequence of mouse kappa V_L regions from subgroup 5 (Kabat et al., *supra*); (human kappa 1) consensus sequence of human V_L regions from subgroup 1 (Kabat et al., *supra*); (human REI) amino acid sequence of a human V_L region (Palm et al. (1975), *supra*); (RH V_L 21.6) amino acid sequence of version L1 of reshaped human 21.6 V_L region; (*) residues that are part of the canonical structures for the CDR loops (Chothia et al., *supra*); (underlined) residues in the human FRs where the amino acid residue was changed.

5 sequence of version L1 of reshaped human 21.6 V_L region; (*) residues that are part of the canonical structures for the CDR loops (Chothia et al., *supra*); (underlined) residues in the human FRs where the amino acid residue was changed.

Table 5
Alignment of amino acid sequences leading to the design of
reshaped human 21.6 heavy chain variable regions.

Kabat	#	FR or CDR	mouse 21.6	mouse 2c (SEQ. ID NO:44)	human 1 (SEQ. ID NO:45)	human 21/28'CL	RH V _H 21.6	Comment
5	1	FR1	E	E	Q	Q	Q	
10	2		V	V	V	V	V	
15	3		Q	Q	Q	Q	Q	
20	4		L	L	L	L	L	
25	5		Q	Q	V	V	V	
30	6		Q	Q	Q	Q	Q	
	7		S	S	S	S	S	
	8		G	G	G	G	G	
	9		A	A	A	A	A	
	10		E	E	E	E	E	
	11		L	L	V	V	V	
	12		V	V	K	K	K	
	13		K	K	K	K	K	
	14		P	P	P	P	P	
	15		G	G	G	G	G	
	16		A	A	A	A	A	
	17		S	S	S	S	S	
	18		V	V	V	V	V	
	19		K	K	K	K	K	
	20		L	L	V	V	V	
	21		S	S	S	S	S	
	22		C	C	C	C	C	
	23		T	T	K	K	K	
	24		A	A	A	A	A	
	25		S	S	S	S	S	
	26		G	G	G	G	G*	
	27		F	F	Y	Y	F*	H1 canonical structure, consider Y in other versions

	28	28		N	N	T	T	<u>N</u> *	H1 canonical structure, on the surface
	29	29		I	I	F	F	I*	H1 canonical structure, consider F in other versions
5	30	30	FR1	K	K	T	T	<u>K</u> *	H1 canonical structure, on the surface
	31	31	CDR1	D	D	S	S	D*	
	32	32		T	T	Y	Y	T*	
	33	33		Y	Y	A	A	Y	
	34	34		I	M	I	M	I*	
	35	35		H	H	S	H	H	
	35A			-	-	-	-	-	
10	35B		CDR1	-	-	-	-	-	
	36	36	FR2	C	W	W	W	W	buried residue, no obvious special role for C
	37	37		V	V	V	V	V	
	38	38		K	K	R	R	R	
	39	39		Q	Q	Q	Q	Q	
15	40	40		R	R	A	A	A	
	41	41		P	P	P	P	P	
	42	42		E	E	G	G	G	
	43	43		Q	Q	Q	Q	Q	
	44	44		G	G	G	R	R	V _L -V _H packing, consider G in other versions
20	45	45		L	L	L	L	L	
	46	46		E	E	E	E	E	
	47	47		W	W	W	W	W	
	48	48		I	I	M	M	M	
	49	49	FR2	G	G	G	G	G	

	50	50	CDR2	R	R	W	W	R	
5	51	51		I	I	I	I	I	
	52	52		D	D	N	N	D	
	52A	53		P	P	P	A	P*	
	52B			-	-	Y	-	-	
	52C			-	-	-	-	-	
10	53	54		A	A	G	G	A*	
	54	55		N	N	N	N	N*	
	55	56		G	G	G	G	G*	
	56	57		Y	N	D	N	Y	
	57	58		T	T	T	T	T	
	58	59		K	K	N	K	K	
	59	60		Y	Y	Y	Y	Y	
15	60	61		D	D	A	S	D	
	61	62		P	P	Q	Q	P	
	62	63		K	K	K	K	K	
	63	64		F	F	F	F	F	
	64	65		Q	Q	Q	Q	Q	
20	65	66	CDR2	G	G	G	G	G	
	66	67	FR3	K	K	R	R	R	
	67	68		A	A	V	V	V	
	68	69		T	T	T	T	T	
	69	70		I	I	I	I	I	
	70	71		T	T	T	T	T	
25	71	72		A	A	A	R	A*	H2 canonical structure, supportin g H2
	72	73		D	D	D	D	D	
	73	74		T	T	T	T	T	
	74	75		S	S	S	S	S	
	75	76		S	S	T	A	A	
30	76	77		N	N	S	S	S	
	77	78		T	T	T	T	T	
	78	79		A	A	A	A	A	
	79	80		Y	Y	Y	Y	Y	
	80	81		L	L	M	M	M	

	81	82		Q	Q	E	E	E	
	82	83		L	L	L	L	L	
5	82A	84		S	S	S	S	S	
	82B	85		S	S	S	S	S	
	82C	86		L	L	L	L	L	
10	83	87		T	T	R	R	R	
	84	88		S	S	S	S	S	
	85	89		E	E	E	E	E	
	86	90		D	D	D	D	D	
15	87	91		T	T	T	T	T	
	88	92		A	A	A	A	A	
	89	93		V	V	V	V	V	
	90	94		Y	Y	Y	Y	Y	
	91	95		F	Y	Y	Y	Y	
20	92	96		C	C	C	C	C	
	93	97		A	A	A	A	A	
	94	98	FR3	R	R	R	R	R*	
	95	99	CDR3	E	G	A	G	E	
25	96	100		G	Y	P	G	G	
	97	101		Y	Y	G	Y	Y	
	98	102		Y	Y	Y	Y	Y	
	99	103		G	Y	G	G	G	
	100	104		N	D	S	S	N	
30	100A	105		Y	S	G	G	Y	
	100B	106		G	X	G	S	G	
	100C	107		V	V	G	-	V	
	100D	108		Y	G	C	-	Y	
	100E	109		A	Y	Y	-	A	
	100F	110		M	Y	R	-	M	
35	100G			-	A	G	-	-	
	100H			-	M	D	-	-	
	100I			-	-	Y	-	-	
	100J			-	-	X	-	-	
	100K			-	-	F	-	-	
	101	111		D	D	D	N	D	
	102	112	CDR3	Y	Y	Y	Y	Y	

103	113	FR4	W	W	W	W	W	
104	114		G	G	G	G	G	
105	115		Q	Q	Q	Q	Q	
106	116		G	G	G	G	G	
107	117		T	T	T	T	T	
108	118		S	X	L	L	L	
109	119		V	V	V	V	V	
110	120		T	T	T	T	T	
111	121		V	V	V	V	V	
112	122		S	S	S	S	S	
113	123	FR4	S	S	S	S	S	

Legend: (Kabat) numbering according to Kabat et al., *supra*; (#) sequential numbering as used in the molecular modelling; (mouse 21.6) amino acid sequence of the V_H region from mouse 21.6 antibody; (mouse 2c) consensus sequence of mouse V_H regions from subgroup 2c (Kabat et al., *supra*); (human 1) consensus sequence of human V_H regions from subgroup 1 (Kabat et al., *supra*); (human 21/28'CL) amino acid sequence of a human V_H region (Dersimonian et al. (1987), *supra*); (RH V_H 21.6) amino acid sequence of version H1 of reshaped human 21.6 V_H region; (*) residues that are part of the canonical structures for the CDR loops (Chothia et al., *supra*); (underlined) residues in the human FRs where the amino acid residue was changed.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5 (i) APPLICANT: Bendig, Mary M.
 Leger, Olivier J.
 Saldanha, Jose
 Jones, S. Tarran

10 (ii) TITLE OF INVENTION: Therapeutic Uses of Humanized Antibodies
 Against Alpha-4 Integrin

(iii) NUMBER OF SEQUENCES: 45

15 (iv) CORRESPONDENCE ADDRESS:
 (A) ADDRESSEE: Townsend and Townsend Khourie and Crew
 (B) STREET: One Market Plaza, Steuart Tower, Suite 2000
 (C) CITY: San Francisco
 (D) STATE: California
 20 (E) COUNTRY: USA
 (F) ZIP: 94105

(v) COMPUTER READABLE FORM:
 (A) MEDIUM TYPE: Floppy disk
 25 (B) COMPUTER: IBM PC compatible
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

30 (vi) CURRENT APPLICATION DATA:
 (A) APPLICATION NUMBER: US 08/186,269
 (B) FILING DATE: 25-JAN-1994
 (C) CLASSIFICATION:

35 (viii) ATTORNEY/AGENT INFORMATION:
 (A) NAME: Smith, William L.
 (B) REGISTRATION NUMBER: 30,223
 (C) REFERENCE/DOCKET NUMBER: 15270-14

40 (ix) TELECOMMUNICATION INFORMATION:
 (A) TELEPHONE: 415-543-9600
 (B) TELEFAX: 415-543-5043

(2) INFORMATION FOR SEQ ID NO:1:

45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 483 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
 (A) NAME/KEY: CDS
 55 (B) LOCATION: 53..430

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

60 ATGAGGGCCC CTGCTCAGAT TTTGGATTG TTGGTCAGGA GACGTTGTAG AA ATG 55
 Met
 1

AGA CCG TCT ATT CAG TTC CTG GGG CTC TTG TTG TTC TGG CTT CAT GGT 103
 Arg Pro Ser Ile Gln Phe Leu Gly Leu Leu Phe Trp Leu His Gly
 65 5 10 15

GCT CAG TGT GAC ATC CAG ATG ACA CAG TCT CCA TCC TCA CTG TCT GCA 151
 Ala Gln Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
 20 25 30

(2) INFORMATION FOR SEQ ID NO:2:

(2) INFORMATION FOR SEQ ID NO:3:

65 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 470 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

5 (A) NAME/KEY: CDS
 (B) LOCATION: 1..420

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATG AAA TGC AGC TGG GTC ATG TTC TTC CTG ATG GCA GTG GTT ACA GGG	48
10 Met Lys Cys Ser Trp Val Met Phe Phe Leu Met Ala Val Val Thr Gly	
1 5 10 15	
GTC AAT TCA GAG GTT CAG CTG CAG CAG TCT GGG GCA GAG CTT GTG AAG	96
15 Val Asn Ser Glu Val Gln Leu Gln Ser Gly Ala Glu Leu Val Lys	
20 25 30	
CCA GGG GCC TCA GTC AAG TTG TCC TGC ACA GCT TCT GGC TTC AAC ATT	144
20 Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile	
35 40 45	
AAA GAC ACC TAT ATA CAC TGT GTG AAG CAG AGG CCT GAA CAG GGC CTG	192
20 Lys Asp Thr Tyr Ile His Cys Val Lys Gln Arg Pro Glu Gln Gly Leu	
50 55 60	
25 GAG TGG ATT GGA AGG ATT GAT CCT GCG AAT GGT TAT ACT AAA TAT GAC	240
25 Glu Trp Ile Gly Arg Ile Asp Pro Ala Asn Gly Tyr Thr Lys Tyr Asp	
65 70 75 80	
30 CCG AAG TTC CAG GGC AAG GCC ACT ATA ACA GCT GAC ACA TCC TCC AAC	288
30 Pro Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn	
85 90 95	
35 ACA GCC TAC CTG CAG CTC AGC AGC CTG ACA TCT GAG GAC ACT GCC GTC	336
35 Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val	
100 105 110	
40 TAT TTC TGT GCT AGA GAG GGA TAT TAT GGT AAC TAC GGG GTC TAT GCT	384
40 Tyr Phe Cys Ala Arg Glu Gly Tyr Tyr Gly Asn Tyr Gly Val Tyr Ala	
115 120 125	
45 ATG GAC TAC TGG GGT CAA GGA ACC TCA GTC ACC GTC TCCTCAGCCA	430
45 Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val	
130 135 140	
45 AAACGACACC CCCATCTGTC TATCCACTGG CCCGGGATCC	470

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

50 (A) LENGTH: 140 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Lys Cys Ser Trp Val Met Phe Phe Leu Met Ala Val Val Thr Gly	
1 5 10 15	
60 Val Asn Ser Glu Val Gln Leu Gln Ser Gly Ala Glu Leu Val Lys	
20 25 30	
65 Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile	
35 40 45	
65 Lys Asp Thr Tyr Ile His Cys Val Lys Gln Arg Pro Glu Gln Gly Leu	
50 55 60	

65 Glu Trp Ile Gly Arg Ile Asp Pro Ala Asn Gly Tyr Thr Lys Tyr Asp
 70 75 80
 5 Pro Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn
 85 90 95
 100 Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val
 105 110
 115 Tyr Phe Cys Ala Arg Glu Gly Tyr Tyr Gly Asn Tyr Gly Val Tyr Ala
 120 125
 130 Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val
 135 140

15 (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
 20 (A) LENGTH: 106 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: protein

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

1 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 5 10 15
 30 Gly Lys Val Thr Ile Thr Cys Lys Thr Ser Gln Asp Ile Asn Lys Tyr
 20 25 30
 35 Met Ala Trp Tyr Gln His Lys Pro Gly Lys Arg Pro Arg Leu Leu Ile
 35 40 45
 His Tyr Thr Ser Ala Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly
 50 55 60
 40 Ser Gly Ser Gly Arg Asp Tyr Ser Phe Asn Ile Ser Asn Leu Glu Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Trp Thr
 85 90 95
 45 Phe Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

50 (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
 55 (A) LENGTH: 107 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

60 (ii) MOLECULE TYPE: protein

60 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

1 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 5 10 15
 65 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ile Lys Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Thr Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Glu Ala Ser Asn Leu Gln Ala Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

5 Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gln Ser Leu Pro Tyr
 85 90 95

10 Thr Phe Gly Gln Gly Thr Lys Leu Gln Ile Thr
 100 105

(2) INFORMATION FOR SEQ ID NO:7:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 106 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

25 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Thr Ser Gln Asp Ile Asn Lys Tyr
 20 25 30

30 Met Ala Trp Tyr Gln Gln Thr Pro Gly Lys Ala Pro Arg Leu Leu Ile
 35 40 45

His Tyr Thr Ser Ala Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Arg Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

40 Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Trp Thr
 85 90 95

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

(2) INFORMATION FOR SEQ ID NO:8:

45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 107 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

55 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

60 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ile Lys Tyr
 20 25 30

65 Leu Asn Trp Tyr Gln Gln Thr Pro Gly Lys Ala Pro Arg Leu Leu Ile
 35 40 45

Tyr Glu Ala Ser Asn Leu Gln Ala Gly Ile Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Arg Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

5 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Gln Ser Leu Pro Tyr
 85 90 95

Thr Phe Gly Gln Gly Thr Lys Leu Gln Ile Thr
 100 105

10 (2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 123 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
1 5 10 15

25 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr
 20 25 30

Tyr Ile His Cys Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile
 35 40 45

30 Gly Arg Ile Asp Pro Ala Asn Gly Tyr Thr Lys Tyr Asp Pro Lys Phe
50 55 60

Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr
65 70 75 80

Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Phe Cys
85 90 95

Ala Arg Glu Gly Tyr Tyr Gly Asn Tyr Gly Val Tyr Ala Met Asp Tyr
 100 105 110

Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
115 120

INFORMATION FOR SEQ ID NO:10:

- (A) LENGTH: 119 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(II) MOLECULES FOR PROCESS

(xi) SEQUENCE DESCRIPTION: SEQ 15 NO.16

Gln Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

60 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met
35 40 45

Gly Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe
 50 55 60

5 Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80

5 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

10 Ala Arg Gly Gly Tyr Tyr Gly Ser Gly Ser Asn Tyr Trp Gly Gln Gly
100 105 110

10 Thr Leu Val Thr Val Ser Ser
115

(2) INFORMATION FOR SEQ ID NO:11:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 123 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

25 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

30 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Thr
20 25 30

Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met
35 40 45

35 Gly Arg Ile Asp Pro Ala Asn Gly Tyr Thr Lys Tyr Asp Pro Lys Phe
50 55 60

40 Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80

45 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

50 Ala Arg Glu Gly Tyr Tyr Gly Asn Tyr Gly Val Tyr Ala Met Asp Tyr
100 105 110

45 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

(2) INFORMATION FOR SEQ ID NO:12:

50 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 119 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

55 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

60 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

65 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Ser Tyr
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe
50 55 60

5 Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

10 Ala Arg Gly Gly Tyr Tyr Gly Ser Gly Ser Asn Tyr Trp Gly Gln Gly
100 105 110

Thr Leu Val Thr Val Ser Ser
115

15 (2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

SEQUENCE CHARACTERISTICS:
(A) LENGTH: 119 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

30 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Ser Tyr
 20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met
35 40 45

Gly Trp Ile Asn Ala Gly Asn Gly Asn Thr Lys Tyr Ser Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Ala Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Tyr Cys

Ala Arg Gly Gly Tyr Phe Gly Ser Gly Ser Asn Tyr Trp Gly Gln Gly

100 105 110

115

(2) INFORMATION FOR SEQ ID NO:14:

(A) LENGTH: 406 base

- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(11) *WILSON* *ET AL.*

(A) NAME/KEY: CDS
(B) LOCATION: 16..393

33

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

5	AAGCTTGGCG CCACC ATG AGA CCG TCT ATT CAG TTC CTG GGG CTC TTG TTG Met Arg Pro Ser Ile Gln Phe Leu Gly Leu Leu L u 1 5 10	51
10	TTC TGG CTT CAT GGT GCT CAG TGT GAC ATC CAG ATG ACA CAG TCT CCA Phe Trp Leu His Gly Ala Gln Cys Asp Ile Gln Met Thr Gln Ser Pro 15 20 25	99
15	TCC TCA CTG TCT GCA TCT CTG GGA GGC AAA GTC ACC ATC ACT TGC AAG Ser Ser Leu Ser Ala Ser Leu Gly Gly Lys Val Thr Ile Thr Cys Lys 30 35 40	147
20	ACA AGC CAA GAC ATT AAC AAG TAT ATG GCT TGG TAC CAA CAC AAG CCT Thr Ser Gln Asp Ile Asn Lys Tyr Met Ala Trp Tyr Gln His Lys Pro 45 50 55 60	195
25	GGA AAA CGT CCT AGG CTG CTC ATA CAT TAC ACA TCT GCA TTA CAG CCA Gly Lys Arg Pro Arg Leu Leu Ile His Tyr Thr Ser Ala Leu Gln Pro 65 70 75	243
30	GGC ATC CCA TCA AGG TTC AGT GGA AGT GGG TCT GGG AGA GAT TAT TCC Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Tyr Ser 80 85 90	291
35	TTC AAC ATC AGC AAC CTG GAG CCT GAA GAT ATT GCA ACT TAT TAT TGT Phe Asn Ile Ser Asn Leu Glu Pro Glu Asp Ile Ala Thr Tyr Tyr Cys 95 100 105	339
40	CTA CAG TAT GAT AAT CTG TGG ACG TTC GGT GGA GGC ACC AAG CTG GAA Leu Gln Tyr Asp Asn Leu Trp Thr Phe Gly Gly Thr Lys Leu Glu 110 115 120	387
45	ATC AAA CGTGAGTGGAA TCC Ile Lys 125	406

(2) INFORMATION FOR SEQ ID NO:15:

40	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 126 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear	
45	(ii) MOLECULE TYPE: protein	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

50	Met Arg Pro Ser Ile Gln Phe Leu Gly Leu Leu Phe Trp Leu His 1 5 10 15	
55	Gly Ala Gln Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser 20 25 30	
60	Ala Ser Leu Gly Gly Lys Val Thr Ile Thr Cys Lys Thr Ser Gln Asp 35 40 45	
65	Ile Asn Lys Tyr Met Ala Trp Tyr Gln His Lys Pro Gly Lys Arg Pro 50 55 60	
70	Arg Leu Leu Ile His Tyr Thr Ser Ala Leu Gln Pro Gly Ile Pro Ser 65 70 75 80	
75	Asn Leu Glu Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp 85 90 95 100 105 110	

Asn Leu Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys
 115 120 125

(2) INFORMATION FOR SEQ ID NO:16:

5

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 454 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

15 (A) NAME/KEY: CDS
 (B) LOCATION: 16..441

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

20	AAGCTTGCCG CCACC ATG GAC TGG ACC TGG CGC GTG TTT TGC CTG CTC GCC Met Asp Trp Thr Trp Arg Val Phe Cys Leu Leu Ala 1 5 10	51
25	GTG GCT CCT GGG GCC CAC AGC CAG GTG CAA CTA GTG CAG TCC GCC GGC Val Ala Pro Gly Ala His Ser Gln Val Gln Leu Val Gln Ser Gly Ala 15 20 25	99
30	GAA GTG AAG AAA CCC GGT GCT TCC GTG AAA GTC AGC TGT AAA GCT AGC Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser 30 35 40	147
35	GGT TTC AAC ATT AAA GAC ACC TAT ATA CAC TGG GTT AGA CAG GCC CCT Gly Phe Asn Ile Lys Asp Thr Tyr Ile His Trp Val Arg Gln Ala Pro 45 50 55 60	195
40	GGC CAA AGG CTG GAG TGG ATG GGA AGG ATT GAT CCT GCG AAT GGT TAT Gly Gln Arg Leu Glu Trp Met Gly Arg Ile Asp Pro Ala Asn Gly Tyr 65 70 75	243
45	ACT AAA TAT GAC CCG AAG TTC CAG GGC CGG GTC ACC ATC ACC GCA GAC Thr Lys Tyr Asp Pro Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp 80 85 90	291
50	ACC TCT GCC AGC ACC GCC TAC ATG GAA CTG TCC AGC CTG CGC TCC GAG Thr Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu 95 100 105	339
55	GAC ACT GCA GTC TAC TAC TGC GCC AGA GAG GGA TAT TAT GGT AAC TAC Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Tyr Tyr Gly Asn Tyr 110 115 120	387
60	GGG GTC TAT GCT ATG GAC TAC TGG GGT CAA GGA ACC CTT GTC ACC GTC Gly Val Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 125 130 135 140	435
	TCC TCA GGTGAGTGGAA TCC Ser Ser	454

60

(2) INFORMATION FOR SEQ ID NO:17:

65

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 142 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Met Asp Trp Thr Trp Arg Val Phe Cys Leu Leu Ala Val Ala Pro Gly
 1 5 10 15

5 Ala His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
 20 25 30

10 Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile
 35 40 45

Lys Asp Thr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu
 50 55 60

15 Glu Trp Met Gly Arg Ile Asp Pro Ala Asn Gly Tyr Thr Lys Tyr Asp
 65 70 75 80

Pro Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Ala Ser
 85 90 95

20 Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val
 100 105 110

25 Tyr Tyr Cys Ala Arg Glu Gly Tyr Tyr Gly Asn Tyr Gly Val Tyr Ala
 115 120 125

Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 130 135 140

30 (2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: DNA (primer)

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CAGAAAGCTT GCCGCCACCA TGAGACCGTC TATTCAG

37

45 (2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: DNA (primer)

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CCGAGGATCC ACTCACGTTT GATTTCCAGC TTGGT

35

60 (2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

65 (ii) MOLECULE TYPE: DNA (primer)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CAGAAAGCTT GCCGCCACCA TGAAATGCAG CTGGGTC

37

5 (2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (primer)

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CCGAGGATCC ACTCACCTGA GGAGACGGTG ACT

33

20 (2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (primer)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

30 GATGGTGACT CTATCTCCTA CAGATGCAGA CAGTGAGGA

39

(2) INFORMATION FOR SEQ ID NO:23:

35 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (primer)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

45 CTGTAGGAGA TAGAGTCACC ATCACTTGCA AG

32

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

55 (ii) MOLECULE TYPE: DNA (primer)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

AGGAGCTTTT CCAGGTGTCT GTTGGTACCA AGCCATATA

39

60 (2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (primer)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

ACCAACAGAC ACCTGGAAAA GCTCCTAGGC TGCTCATACA T

41

5 (2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (primer)

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GCAGGCTGCT GATGGTGAAA GTATAATCTC TCCCAGACCC

40

20 (2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (primer)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

30 ACTTTCACCA TCAGCAGCCT GCAGCCTGAA GATATTGCAA CT

42

(2) INFORMATION FOR SEQ ID NO:28:

35 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 59 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: DNA (primer)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

45 CCGAGGATCC ACTCACGTTT GATTTCCACC TTGGTGCCTT GACCGAACGT CCACAGATT

59

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

55 (ii) MOLECULE TYPE: DNA (primer)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GGAAAAGCTC CTAGGCTGCT CATATATTAC ACA

33

60 (2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (primer)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

CCGAGGATCC ACTCACGTTT GATTCCACC TTTGTGCC

38

5 (2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 51 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (primer)

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

AACCCAGTGT ATATAGGTGT CTTTAATGTT GAAACCGCTA GCTTTACAGC T

51

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 67 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (primer)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

30 AAAGACACCT ATATACACTG GGTTAGACAG GCCCCTGGCC AAAGGCTGGA GTGGATGGGA

60

AGGATTG

67

35 (2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (primer)

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

GACCCGGCCC TGGAACTTCG GGTCAT

26

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 66 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (primer)

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

60 GACCCGAAGT TCCAGGGCAG GGTCACCATC ACCGCAGACA CCTCTGCCAG CACCGCCTAC

60

ATGGAA

66

65 (2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 64 base pairs
- (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: DNA (primer)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

CCATAGCATA GACCCCGTAG TTACCATAAT ATCCCTCTCT GGCGCAGTAG TAGACTGCAG 60

10 TGTC 64

(2) INFORMATION FOR SEQ ID NO:36:

15 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 63 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: DNA (primer)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

GGTAACTACG GGGTCTATGC TATGGACTAC TGGGGTCAAG GAACCCTTGT CACCGTCTCC 60

25 TCA 63

(2) INFORMATION FOR SEQ ID NO:37:

30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 37 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: DNA (primer)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

40 CCAGGGCCGG GTCACCATCA CCAGAGACAC CTCTGCC 37

(2) INFORMATION FOR SEQ ID NO:38:

45 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: DNA (primer)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

55 CAGGCCCTG GCCAAGGGCT GGAGTGG 27

(2) INFORMATION FOR SEQ ID NO:39:

60 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 17 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

65 (ii) MOLECULE TYPE: DNA (primer)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

TACGCAAACC GCCTCTC

17

(2) INFORMATION FOR SEQ ID NO:40:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: DNA (primer)

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GAGTGCACCA TATGCGGT

18

15 (2) INFORMATION FOR SEQ ID NO:41:

20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 116 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: protein

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

30 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

35 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
20 25 30

40 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val
35 40 45

45 Gly Tyr Ile Asp Pro Phe Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe
50 55 60

50 Lys Gly Lys Val Thr Met Thr Val Asp Thr Ser Thr Asn Thr Ala Tyr
65 70 75 80

55 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

60 Ala Arg Gly Gly Asn Arg Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110

65 Thr Val Ser Ser
115

50 (2) INFORMATION FOR SEQ ID NO:42:

55 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 109 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

60 (ii) MOLECULE TYPE: protein

65 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

70 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
1 5 10 15

75 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Asp Ile Ser Asn
20 25 30

Tyr L u Asn Trp Tyr Gln Gln Lys Pro Gly Gly Ser Pro Lys Leu Leu
 35 40 45

Ile Tyr Tyr Ala Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser
 5 50 55 60

Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu
 65 70 75 80

Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro
 10 85 90 95

Pro Arg Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys
 15 100 105

15 (2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 114 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

30 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ser Leu Val Xaa
 20 25 30

Xaa Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys
 35 35 40 45

Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Glu Ser Gly Val
 50 55 60

40 Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
 65 70 75 80

Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
 85 90 95

45 Tyr Asn Ser Leu Pro Glu Trp Thr Phe Gly Gln Gly Thr Lys Val Glu
 100 105 110

Ile Lys

50 (2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 125 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

55 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

65 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr
 20 25 30

Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile
 35 40 45

Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe
50 55 60

5 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr
65 70 75 80

Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
10 85 90 95

Ala Arg Gly Tyr Tyr Tyr Asp Ser Xaa Val Gly Tyr Tyr Ala Met
100 105 110

Asp Tyr Trp Gly Gln Gly Thr Xaa Val Thr Val Ser Ser
15 115 120 125

15 (2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:
20 (A) LENGTH: 129 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: protein

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

30 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30

35 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Trp Ile Asn Pro Tyr Gly Asn Gly Asp Thr Asn Tyr Ala Gln Lys
50 55 60

40 Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Ser Thr Ala
65 70 75 80

45 Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Ala Pro Gly Tyr Gly Ser Gly Gly Cys Tyr Arg Gly Asp
100 105 110

50 Tyr Xaa Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125

WHAT IS CLAIMED IS:

1 1. Use of a humanized antibody to alpha-4 integrin in
2 the manufacture of a medicament for treating a disease
3 selected from the group consisting of asthma, atherosclerosis,
4 AIDS dementia, diabetes, inflammatory bowel disease,
5 rheumatoid arthritis, transplant rejection, graft versus host
6 disease, tumor metastasis, nephritis, atopic dermatitis,
7 psoriasis, myocardial ischemia, and acute leukocyte mediated
8 lung injury.

1 2. The use according to claim 1, wherein the disease is
2 asthma.

1 3. The use according to claim 1, wherein the disease is
2 atherosclerosis.

1 4. The use according to claim 1, wherein the disease is
2 AIDS dementia.

1 5. The use according to claim 1, wherein the disease is
2 diabetes.

1 6. The use according to claim 1, wherein the disease is
2 inflammatory bowel disease.

1 7. The use according to claim 1, wherein the disease is
2 rheumatoid arthritis.

1 8. The use according to claim 1, wherein the disease is
2 transplant rejection.

1 9. The use according to claim 1, wherein the disease is
2 graft versus host disease.

1 10. The use according to claim 1, wherein the disease is
2 tumor metastasis.

1 11. The use according to claim 1, wherein the disease is
2 nephritis.

1 12. The use according to claim 1, wherein the disease is
2 atopic dermatitis.

1 13. The use according to claim 1, wherein the disease is
2 psoriasis.

1 14. The use according to claim 1, wherein the disease is
2 myocardial ischemia.

1 15. The use according to claim 1, wherein the disease is
2 acute leukocyte-mediated lung injury.

1 16. The use according to claim 17, wherein the disease
2 is adult respiratory distress syndrome.

1 17. The use according to any one of the preceding claims
2 wherein the humanized antibody is a humanized form of the
3 mouse 21.6 antibody.

1 18. The use according to claim 17, wherein the humanized
2 antibody comprises a humanized heavy chain and a humanized
3 light chain:

4 (1) the humanized light chain comprising three
5 complementarity determining regions (CDR1, CDR2 and CDR3)
6 having amino acid sequences from the corresponding
7 complementarity determining regions of the mouse 21-6
8 immunoglobulin light chain variable domain designated SEQ. ID.
9 No. 2, and a variable region framework from a human kappa
10 light chain variable region framework sequence except in at
11 least one position selected from a first group consisting of
12 L45, L49, L58 and L69, wherein the amino acid position is
13 occupied by the same amino acid present in the equivalent
14 position of the mouse 21-6 immunoglobulin light chain variable
15 region framework; and

28 wherein the humanized immunoglobulin specifically binds
29 to alpha-4 integrin with a binding affinity having a lower
30 limit of about 10^7 M⁻¹ and an upper limit of about five-times
31 the binding affinity of the mouse 21-6 immunoglobulin.

1 19. The use according to claim 18, wherein the humanized
2 light chain variable region framework is from an RE1 variable
3 region framework sequence except in at least one position
4 selected from the first group, and except in at least one
5 position selected from a third group consisting of positions
6 L104, L105 and L107, wherein the amino acid position is
7 occupied by the same amino acid present in the equivalent
8 position of a kappa light chain from a human immunoglobulin
9 other than RE1.

1 20. The use according to claim 19, wherein the humanized
2 heavy chain variable region framework is from a 21/28'CL
3 variable region framework sequence.

1 21. The use according to claim 20, wherein the humanized
2 light chain variable region framework comprises at least three
3 amino acids from the mouse 21.6 immunoglobulin at positions in
4 the first group and three amino acids from the kappa light
5 chain from the human immunoglobulin other than REI at
6 positions in the third group, and the humanized heavy chain
7 variable region framework comprises at least five amino acids

8 from the mouse 21.6 immunoglobulin at positions in the second
9 group.

1 22. The use according to claim 21, wherein the humanized
2 light chain variable region framework is identical to the RE1
3 light chain variable region framework sequence except for the
4 at least three positions from the first group and the three
5 positions from the third group, and the heavy chain variable
6 region framework is identical to the 21/28'CL heavy chain
7 variable region framework sequence except for the at least
8 five positions from the second group.

1 23. The use according to claim 22, wherein the at least
2 three positions from the first group are positions L45, L58
3 and L69, and at the least five positions from the second group
4 are positions H27, H28, H29, H30 and H71.

1 24. The use according to claim 23, wherein the humanized
2 light chain comprises complementarity determining regions that
3 are identical to the corresponding complementarity determining
4 regions of the mouse 21-6 heavy chain, and the humanized heavy
5 chain comprises complementarity determining regions that are
6 identical to the corresponding complementarity determining
7 regions of the mouse 21-6 heavy chain, except that the CDR3
8 region of the humanized heavy chain may or may not comprise a
9 phenylalanine residue at position H98.

1 25. The use according to claim 24, wherein the amino
2 acid sequence of the mature light chain variable region is the
3 sequence designated La (SEQ. ID NO:7) in Fig. 6 and the amino
4 acid sequence of the mature heavy chain variable region is Ha
5 (SEQ. ID NO:11) in Fig 7.

1 26. The use according to claim 25, wherein the humanized
2 antibody is a Fab fragment.

1/16

1 atgaggcccctgctcagattttggattcttggtcaggagacgttgt
 1 -----
 tactccggggacgagtcataaaaacctaagaaccagtcctctgcaaca
 ACTAGTCGACATGAGGGCCCCTGCTCAGTTTGGCTTCTTG-3'

A A C AA
 MKV4 PRIMER

49 agaaaatgagaccgtctattcagttcctggggctcttgttgttctggcttcatgg
 49 -----
 tctttactctggcagataagtcaaggaccccgagaacaacaagaccgaagtacc

[M R P S I Q F L G L L L F W L H G
 LEADER

103 tgctcagtgtgacatccagatgacacagtctccatcctcactgtctgcacatctct
 103 -----
 acgagtcacactgttaggtctactgtgtcagaggtaggagtgacagacgtagaga

A Q C] [D I Q M T Q S P S S L S A S L
 FR1

157 gggaggcaaagt caccatcacttgcaagacaagccaagacattaacaagtataat
 157 -----
 ccctccgtttagtggtagtgaacgttctgttgggtctgttaattgttcatata

G G K V T I T C] [K T S Q D I N K Y M
 CDR1

211 ggcttggtaccaacacaaggcctggaaaacgtcctaggctgctcatacattacac
 211 -----
 ccgaaccatggtgtgttggaccccttgcaggatccgacgagatgtaatgtg

A] [W Y Q H K P G K R P R L L I H] [Y T
 FR2

265 atctgcattacagccaggcatccatcaagggttcagtgaaagtgggtctgggag
 265 -----
 tagacgtaatgtcggtccgttagggtagttccaagtcaccttacccagaccctc

S A L Q P] [G I P S R F S G S G S G R
 CDR2

FIG. 1-1.

2/16

319 agattattccttcaacatcagcaacctggagcctgaagatattgcaacttatta

tctaataaggaagttgttagtcgttggacctcgacttctataacgttgaataat
D Y S F N I S N L E P E D I A T Y Y
FR3

373 ttgtctacagtatgataatctgtggacgttcggtggaggcaccaagctggaaat

aacagatgtcatactattagacacacctgcaagccacccgtggacccctta
C] [L Q Y D N L W T] [F G G G T K L E I
CDR3 FR4

427 MOUSE KAPPA PRIMER
3' -GTAGAAGGGTAGGTGGCCCT
caaacgggctgatgctgcaccaactgtatccatcttcccaccatccacccggga

gtttgcccgactacgacgtggttgacataggtagaagggtggtaggtggccct
K]
AGG-5'
tcc
481 ---
agg

FIG. 1-2.

3/16

atgaaatgcagctgggtcatgttcttctgtggcagtggttacaggg
 1 -----
 tactttacgtcgaccaggataacaagaaggactaccgtcaccaatgtccc
 ACTAGTCGACATGAAATGCAGCTGGGTACATCTTCTTC-3'
 G

MHV1 PRIMER
 [M K C S W V M F F L M A V V T G
 LEADER

gtcaattcagagggttcagctgcagcagtctggggcagagcttgtgaagccaggg
 49 -----
 cagtttaagtctccaaagtgcacgtcgtcagacccgtctcgaacacttcggtccc
 V N S] [E V Q L Q Q S G A E L V K P G
 FR1

gcctcagtcagttgtcctgcacagcttctggcttcaacattaaagacacctat
 103 -----
 cggagtcagttcaacaggacgtgtcgaagaccgaagttgttaattctgtggata
 A S V K L S C T A S G F N I K] [D T Y
 CDR1

atacactgtgtgaagcagaggcctgaacaggcctggagtggattgaaaggatt
 157 -----
 tatgtgacacacttcgtctccggacttgtccggacctcacctaaccctcctaa
 I H] [C V K Q R P E Q G L E W I G] [R I
 FR2

gatcctgcgaatggttataactaaatatgacccgaagttccagggcaaggccact
 211 -----
 ctaggacgcttaccaatatgatttatactggcttcaggtcccggtccgggtga
 D P A N G Y T K Y D P K F Q G] [K A T
 CDR2

ataacagctgacacatcctccaaacacagcctacctgcagctcagcagcctgaca
 265 -----
 tattgtcgactgtgttaggaggtgtgtcgatggacgtcgactcgactgt
 I T A D T S S N T A Y L Q L S S L T
 FR3

FIG. 2-1.

4/16

319 tctgaggacactgccgtctatttctgtgctagagagggatattatggtaactac

agactcctgtgacggcagataaagacacgatctctccctataataaccattgatg

S E D T A V Y F C A R] [E G Y Y G N Y
CDR3

373 ggggtctatgctatggactactggggtaaggaacctcagtcaccgtctcctca

ccccagatacgatacctgatgaccccagttccttggagtcaagtggcagaggagt

G V Y A M D Y] [W G Q C T S V T V S S]

MOUSE GAMMA-1 PRIMER

3' -GTAGACAGATAGGTGACCGGGCCCTAGG-5
427 gccaaaacgacaccccatctgtctatccactggcccggtatcc

cggtttgctgtggggtagacagataggtgaccggccctagg

S S]

FIG. 2-2.

5/16




FIG. 3A.




FIG. 3B.

6/16




FIG. 4.




FIG. 5.

7/16

	FR1	CDR1	FR2	CDR2
	1	2	3	4
	12345678901234567890123	45678901234	567890123456789	0123456
*	*	*	*	*

21.6	DIQMTQSPSSLSASLGGKVTTTC	KTSQDINKYMA	WYQHKGKRPRLIH	YTSALQP
REI	DIQMTQSPSSLSASVGDRVTTTC	QASQDIKIYLN	WYQQTPGKAPKLLY	EASNLLQA
La	DIQMTQSPSSLSASVGDRVTTTC	KTSQDINKYMA	WYQQTPGKAPLLIH	YTSALQP
Lb	-----	-----	-----R-----	-----
	FR3	FR4		
	6	7	8	9
	78901234567890123456789012345678	9012345678	901234567	8901234567
*	*	*	*****	
21.6	GIPSREFSGSGSGRDYSFNISNLEPEDIATYYC	LQYDNL-WT	FGGGTKLEIK	
REI	GVPSREFSGSGSGTDTFTISSLQPEDIATYYC	QQYQSLPYT	FGQGTTKLQIT	
La	<u>GIPSREFSGSGSGRDYTFITISSLQPEDIATYYC</u>	LQYDNL-WT	FGQGTTKVEIK	
Lb	-I-----R-----	-----	-----VE-K	

FIG. 6.

8/16

	FR1	2	3	CDR1	4	FR2	5	CDR2	6
1	123456789012345678901234567890	12345	67890123456789	67890123456789	0123456789012345	0123456789012345	0123456789012345	0123456789012345	
	*****	***	*	*	*	*	*	*	

21.6 EVQLQQSGAELVKPGASVKSCKASGFNIK DTYIH CVKQRPEQGLEWIG RIDPANGYTKYDPKFQG

2*CL QVQLVQSGAEVKKPGASVKSCKASGFNIK DTYIH WVRQAPGQRLEWMG WINAGNGNTKYSQKFQG

Ha QVQLVQSGAEVKKPGASVKSCKASGFNIK DTYIH WVRQAPGQRLEWMG WINAGNGNTKYSQKFQG

Hb -----FNIK -----G-----

Hc -----FNIK -----

	FR3	8	9	CDR3	10	FR4	11
7	67890123456789012ABC345678901234	567890ABCDEF12	*	34567890123	*		

21.6 KATITADTSNTAYLQLSSLTSEDTAVYFCAR EGYYGNYGVYAMDY WGQGTSVTVSS

2*CL RVTITRDTSASTAYMELSSLRSEDTAVYFCAR GGYYGSGS----NY WGQGTLVTVSS

Ha RVTITADTSASTAYMF -----RSEDTAVYFCAR EGYYGNYGVYAMDY WGQGTLVTVSS

Hb -----A-----

Hc -----A-----

FIG. 7.

9/16




FIG. 8.

10/16




FIG. 9.

HindIII KOZAK SEQUENCE 11/16

aagcttgccgcccaccatgagaccgtctattcagttcctggggctttgttgttc
 1 -----
 ttcgaacggcggtggtaactctggcagataagtcaaggaccccgagaacaacaag

[M R P S I Q F L G L L L F
 LEADER

tggcttcatggtgctcagtgtgacatccagatgacacagtctccatcctcactg
 55 -----
 accgaagtaccacgagtcacactgttaggtctactgtgtcagaggttaggagtgac

W L H G A Q C] [D I Q M T Q S P S S L
 FR1

tctgcatctGTAgaGATAGAgtcaccatcacttgcagacaagccaagacatt
 109 -----
 agacgtagaCATcctCTATCTcagtggtagtgaacgttctgtcggtctgtaa

S A S V G D R V T I T C] [K T S Q D I
 CDR1

aacaagtatatggcttggtagccaaCAGACACtggaaaGCTcctaggctgctc
 163 -----
 ttgttcatataccgaaccatggtagtGTCTGTggacctttCGAggatccgacgag

N K Y M A] [W Y Q Q T P G K A P R L L
 FR2

atacattacacatctgcattacagccaggcatccatcaaggtagtggaaagt
 217 -----
 tatgtaatgttagacgtaatgtcggtccgttaggtagttccaaagtcacctca

I H] [Y T S A L Q P] [G I P S R F S G S
 CDR2

gggtctggagagattatACTttcACCatcagcAGCctgCAGcctgaagatatt
 271 -----
 cccagaccctctctaataTGAaagTGGtagtcgTCGgacGTCggacttctataa

G S F R D Y T F T I S S L Q P E D I
 FR3

FIG. 10-1.

12/16

325 gcaacttattattgtctacagtatgataatctgtggacgttcggtCAAAGgcacc

cgttgaataataacagatgtcatactattagacacacctgcaagccaGTTccgtgg

A T Y Y C] [L Q Y D N L W T] [F G Q G T
CDR3 FR4

SPLICE DONOR SITE BamHI

379 aagGTGgaaatcaaaacgtgagtggatcc

ttcCACcttagttgcactcacctagg

K V E I K]

FIG. 10-2.

HindIII KOZAK SEQUENCE

1 AAGCTTGCCGCCACCATGGACTGGACCTGGCGCGTGTGTTGCCTGCTGCCGTG

TTCGAACGGCGGTGGTACCTGACCTGGACCGCGCACAAACGGACGAGCGGCAC

[M D W T W R V F C L L A V
LEADER

55 GCTCCTGGGGCCCACAGCCAGGTGCAACTAGTGCAGTCCGGGCCGAAGTGAAG

CGAGGACCCCGGGTGTGCGGTCCACGTTGATCACGTCAGGCCGCGCTTCACCTC

A P G A H S] [Q V Q L V Q S G A E V K

109 AAACCCGGTGCTTCCGTGAAAGTCAGCTGTAAAGCTAGCGGTttcaacattaaa

TTTGGGCCACGAAGGCACTTCAGTCACATTCGATGCCAaagtgttaattt

K P G A S V K V S C K A S G F N I K] [
FR1

163 gacacctatacacacTGGGTTAGACAGGCCCTGGCCAAAGGCTgGAGTGGATg

ctgtggatatatgtgACCCAATCTGTCCGGgGaCCGGTTtCCGAcCTCACCTAc

D T Y I H] [W V R Q A P G Q R L E W M
CDR1 FR2

FIG. 11-1.

13/16

217 G Gaaggattgatcctgcgaatggttatactaaatatgacccgaagttccagggc

 CCTtcctaactaggacgcttaccaatatgatttatactgggcttcaaggtcccg

G] [R I D P A N G Y T K Y D P K F Q G] [
 CDR2

271 cgggtcACCatcACCGcaGACACCTCTgccagcACCGCCTACATGGAACTGTCC

 gcccagTGGtagTGGcgtCTGTGGAGAcggtcgTGGCGGATGTACCTTGACAGG

R V T I T A D T S A S T A Y M E L S
 FR3

325 AGCCTGCGCTCCGAGGACACTGCAGTCTACTACTGCGCCagagagggatattat

 TCGGACGCGAGGCTCCTGTGACGTAGATGATGACGCGGtctctccctataata

S L R S E D T A V Y Y C A R] [E G Y Y

379 ggttaactacggggtctatgctatgGACTAcTGGGGtCAaGGaACCCTTGTCAACC

 ccattgatgccccagatacgatacCTGATgACCCCaGTtCCtTGGGAACAGTGG

G N Y G V Y A M D Y] [W G Q G T L V T
 CDR3 FR4

SPLICE DONOR SITE BamHI

GTCTccTCAGGTGAGTGGATCC

433 -----
 CAGaggAGTCCACTCACCTAGG

V S S]

FIG. 11-2.

14/16




FIG. 12A.




FIG. 12B.




FIG. 13A.




FIG. 13B.




FIG. 14.

16/16




FIG. 15.




FIG. 16.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/18807

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 39/395

US CL :424/130.1, 133.1, 141.1, 143.1, 144.1, 153.1, 154.1, 173.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/130.1, 133.1, 141.1, 143.1, 144.1, 153.1, 154.1, 173.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG, BIOSIS, CA, EMBASE, MEDLINE, WPI
search term: alpha-4-integrin, 21-6, 21/28'cl, inflammation

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Agents Actions, Volume 39, issued 1993, Monshizadegan et al., "VLA-4-Dependent Adhesion Activities of U937 Cells and Guinea Pig Bronchoalveolar Lavage Leukocytes", pages C177-C179, see entire document.	1-26
Y	WO, A, 91/03252 (WAYNER) 21 March 1991, see entire document.	1-26
Y	WO, A, 90/07861 (PROTEIN DESIGN LABS, INC.) 26 July 1990, see entire document.	1-26
Y	Protein Engineering, Volume 4, Number 7, issued 1991, Kettleborough et al., "Humanization of a Mouse Monoclonal Antibody by CDR-Grafting the Importance of Framework Residues on Loop Conformation", pages 773-783, see entire document.	1-26

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

25 FEBRUARY 1997

Date of mailing of the international search report

18 MAR 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PHILLIP GAMBLE

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)★